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Human Herpes virus-8 (HHV-8) is the known etiologic agent for several
malignant pathologies, including Kaposi’s sarcoma (KS), the most common tumor in
children in sub-Saharan Africa. Saliva is implicated as the culprit of transmission;
however there is a paucity of information regarding transmission to young children. In
this study, we investigated the hypothesis that household behaviors exposing the
susceptible child to saliva increase the risk of transmission of HHV-8 to that child.
To test our hypothesis a large prospective cohort study in Lusaka, Zambia,
enrolling 464 young children and their households, was followed for 48 months. Sociodemographics, health histories, feeding and child-rearing behaviors were assessed.
At enrollment, 75 HHV-8 positive children were analyzed for existing risk factors
contributing to HHV-8 seropositivity. Analysis for independent variables found that for
each additional HHV-8 positive household member, there was 2.5 greater odds for the
child to be HHV-8 positive (P < 0.01). Of the household saliva sharing risk behaviors, a
primary caregiver testing temperature of food prior to feeding to a child posed a 2.4
greater odds (P = 0.01). A child having been breastfed offered a decreased risk (OR 0.3,
P < 0.01).
Of the enrolled children, 270 children were available for longitudinal analysis. Of
these, 137 children seroconverted to become HHV-8 positive, an incidence of 29.94 per

100 child-years. Most significant independent behavioral risk factors for HHV-8
seroconversion included increased risk with current breastfeeding (HR 2.1, P = 0.002),
increased risk with use of pacifier (HR 9.0, P = 0.01), and greater risk with household
members blowing on food prior to sharing with child (HR 2.8, P = 0.05). Other studies
in this report include development of an HHV-8 serodiagnostic assay.
Taken together, this report describes the epidemiology of HHV-8 transmission to
a susceptible child within households, and the association with saliva sharing behaviors.
Our results support the need for increased public awareness and education regarding risks
of viral transmission with child-rearing behaviors that expose the child to saliva.
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CHAPTER 1: LITERATURE REVIEW
THE HERPESVIRUSES
The Herpesviridae is one of the largest families of viruses, with more than 100
members isolated from almost all mammalian species (reviewed in [1]). Assignment of a
virus into the herpesvirus family is based on morphology of the virus particle and
genomic similarity. Under an electron microscope, the virions of different members of
the Herpesviridae family are indistinguishable. Each consists of four well-defined
components including the core, capsid, tegument, and envelope. The core contains a
double-stranded DNA genome, which is located inside an icosadeltahedral capsid that is
approximately 100 nm in diameter and contains 162 capsomeres (reviewed in [1]). A
layer of proteins collectively known as the tegument is located between the capsid and
the viral envelope. The variation in size of mature herpes viruses (120 to 300 nm) is
mostly due to differences in the size of the individual viral teguments. The tegument
arrangement is typically asymmetrical with some herpetic members showing less
ambiguous tegumental structures than others. Structurally the tegument connects the
capsid to the envelope, while functionally acting as a reservoir for viral proteins which
are required during the initial phases of viral infection [2]. Several herpesviral tegument
proteins have been shown to play a role in evading the host immune response. For
example, the p65 protein of human cytomegalovirus blocks the presentation of viral
immediate-early proteins by MHC class I molecules, and interferes with NK cell
responses by interacting with an NK cell-activating receptor [3].
The outermost framework of the herpes virion is the envelope, which is derived
from cell nuclear membranes and is impregnated with various viral glycoproteins. By
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interacting with cellular receptors during early phases of infection, these glycoproteins
help to determine host range of specific herpesviruses. All herpesvirus infections have a
limited cellular tropism within their specific host, determining their sites of infection and
latency. Most herpesviruses recognize multiple cellular receptors, and the majority makes
initial contact with cells by binding to glycosaminoglycans such as heparin sulfate on the
cell surface, followed by interaction with other specific cellular receptors [4].
Some important herpesviruses of domestic animals include Suid herpesvirus 1,
the cause of pseudorabies; bovine herpesvirus 1, the cause of infectious bovine
rhinotracheitis; feline herpesvirus 1, the cause of feline viral rhinotracheitis; and equine
herpesviruses, which can cause diseases of the respiratory, reproductive, and nervous
system of horses. Marek’s disease of chickens is caused by an oncogenic herpesvirus that
can cause T cell lymphomas, along with other syndromes [5].
Eight viruses in the family Herpesviridae are of specific interest because of their
capability to cause disease in humans (see table 1). Clinically significant human
herpesviruses include the herpes simplex viruses (HSV-1 and HSV-2), varicella zoster
virus (VZV), Epstein-Barr virus (EBV), cytomegalovirus (CMV), and Kaposi’s sarcomaassociated herpesvirus (KSHV), also known as HHV-8.
HERPESVIRUS CLASSIFICATIONS
Herpesviruses have been classified into three subfamilies, α, β and γ, by the
Herpesvirus Study Group of the International Committee on the Taxonomy of Viruses.
Membership into a particular subfamily is based on its biologic properties. See Table 1
for short description of the herpesvirus subfamilies, associated diseases in humans,
cellular tropism and the means of transmission in humans. Although classification does
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not rely on DNA sequence homology, sequence analysis of the DNA polymerase gene
and the glycoprotein B gene have allowed researchers to identify and appropriately
characterize the viral subfamilies [6]
Alphaherpesviruses
The alphaherpesvirinae subfamily is divided into two genera; Simplexvirus,
which includes herpes simplex virus-1 (HSV-1), herpes simplex virus-2 (HSV-2) and
Varicellovirus, which includes varicella-zoster virus (VZV), also called human
herpesvirus-3 (HHV-3). Alphaherpesviruses are known for causing painful fluid-filled
epithelial vesicular lesions, HSV-1 is the causative agent for oro-facial fever blisters, also
known as common cold sores. The primary route of HSV-1 transmission is via saliva;
however it can also be transmitted via an oro-genital route, causing genital lesions [7, 8].
HSV-2 is known as a sexually transmitted disease, responsible for genital herpes. A risk
of transmission to newborns also exists correlating to maternal viral shedding at delivery
(reviewed in [8]). VZV causes varicella (chicken pox), and herpes zoster (shingles).
After primary infection (chicken pox syndrome), VZV maintains latency in sensory
ganglia and can reactivate later in life, producing herpes zoster [9].
Alphaherpeviruses have a short replicative cycle in the host, grow and spread
rapidly in cell culture, and share the establishment of latent infections in sensory ganglia.
Members of this subfamily are often referred to as neurotropic herpes viruses [6].
Betaherpesviruses
The betaherpesvirinae subfamily consists of two genera; Cytomegalovirus, which
includes human herpesvirus-5 or cytomegalovirus (CMV), and Roseolovirus, which
includes human herpesvirus-6 (HHV-6A and HHV-6B) and human herpesvirus-7 (HHV-
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7). HHV-6 and HHV-7 are ubiquitous in the general population, but cause disease in
immunocompromised patients and in infants. The disease Exanthema subitum, also
known as roseola infantum can be caused by both HHV-6 strains and HHV-7 [10]. This
disease occurs in young children and is characterized by a generalized macular or popular
rash on the face or trunk, accompanied by high fever [11]. Although usually mild,
convulsions and encephalopathy may accompany the infection [12].
CMV is considered to be ubiquitous in adults, and infection can be unnoticed in
healthy individuals. However life threatening diseases can develop for immune
compromised individuals infected with CMV, such as HIV-positive individuals, organ
transplant recipients, and newborn infants [13]. Congenitally acquired CMV is perhaps
the most clinically significant form, resulting in infant mortality or permanent disabilities
such as hearing loss and developmental disabilities (reviewed in [14]). CMV
transmission is known to occur via the sexual route in adults, (reviewed in [14]), and
through breastfeeding to young children [15].
Betaherpesviruses have a fairly restricted host range, with a long reproductive
cycle, both in cell culture and within the infected host. These viruses are cytopathic in
culture; infected cells demonstrate morphological changes and cytomegalia (cellular
enlargement) [6].
Gammaherpesviruses
The gammaherpesvirinae subfamily includes HHV-8 and human herpesvirus-4
(HHV-4) or Epstein-Barr virus (EBV), the only other gamma herpesvirus infecting
humans. Gammaherpesviruses have a restricted host range, viral replication generally
restricted to either T or B-cell lymphocytes, and latent infections in lymphoid tissues [6].
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The gammaherpesviruses subfamily contains two genera, Lymphocrptovirus
(LCV) (gamma-1), and Rhadinovirus (RDV) (gamma-2). EBV is the only LCV and
HHV-8 is the only RDV discovered known to infect humans. LCV is found only in
primates, but RDV can be found in both primates and other mammals [6].
EPSTEIN BARR VIRUS
Epstein-Barr virus is implicated in numerous clinical diseases, including
infectious mononucleosis, Burkitt’s lymphoma, Hodgkin’s disease, Blymphoproliferative disease, nasopharyngeal carcinoma, and oral hairy leukoplakia.
There is a well-established relationship between EBV and oncogenesis. Several genes
encoded by EBV are essential for inducing transformation of B cells, including EBNA-1,
EBNA-2, EBNA-3A, EBNA-3C and LMP-1 [16]. The cellular transformation is a
complex process, involving cooperative interactions between several viral proteins,
however the pathogenesis is thought to also include genetic aberrations, as occurs in
Burkitt’s lymphoma in which the c-myc gene is translocated [17].
Epstein-Barr virus routes of transmission have been well established, and serve as
a prototype when studying HHV-8 transmission. Viral DNA is readily isolated in saliva
and salivary exchange is the accepted mode of transmission for EBV. Transmission
occurs via intimate kissing, sharing drinking glasses, and children sharing of toys. Viral
shedding in saliva has been demonstrated to persist for an extended length of time post
infection. Fafi-Kremer et al. (2005) demonstrated that in patients evaluated after
infectious mononucleosis, EBV viral DNA persisted for 6 months post disease onset,
whereas viral load decreased considerably from PBMC’s and rapidly disappeared from
plasma [18].
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HUMAN HERPESVIRUS-8
HHV-8 is the most recently discovered human herpesvirus family member, the
etiologic agent for Kaposi’s sarcoma (KS). HHV-8 was initially isolated from KS lesions
in patients with acquired immunodeficiency syndrome (AIDS) using representational
difference analysis [19]. This virus was further characterized using an infected B-cell
line derived from an AIDS-related lymphoma patient and a genomic library made from a
KS lesion to be a gamma-2 herpesvirus [19, 20].
HHV-8 has sequence homology and genomic organization that is similar to both
EBV and another well-known Rhadinovirus, herpesvirus saimiri, a T-cell tropic virus
known to cause lymphoma in primate hosts such as squirrel monkeys, but also has many
unique sequences [19, 21].
Strain variation has been found among HHV-8 isolates. Five HHV-8 variants
(groups A to E) have been identified based on analysis of gene products from two HHV-8
genes, ORF-K1 and ORF-15. Groups A and C predominate in Europe and North
America, B is dominant in Africa, D and E are found in the Pacific Islands and
Amerindian populations (reviewed in [22]).
HHV-8 Genome organization
The HHV-8 viral DNA genome consists of a single, long, unique region
containing all the coding regions and is similar to the genome of herpesvirus saimiri. The
coding region is flanked by variable numbers of direct terminal repeats. HHV-8
possesses approximately 26 core genes, which are highly conserved across the alpha-,
beta-, and gammaherpesviruses. These genes are responsible for gene regulation,
nucleotide metabolism, DNA replication, and virion maturation and structure (reviewed
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in [1]). HHV-8 also has at least 12 human host gene homologs, not shared by other
human herpesviruses. Some of these genes retain host function, or have been modified
and implicated in oncogenesis. These include genes encoding viral Bcl-2, cyclin D,
interleukin-6, G-protein-coupled receptor, and ribonucleotide reductase [23] (reviewed in
[1]). In addition HHV-8 has a number of genes and regulatory proteins that interact with
the host immune response, functioning in evasion of host cellular defense mechanisms
[24].
Latent phase of infection
A hallmark of all herpesviruses is that after infecting a host cell, herpesviruses
cycle between two phases: lytic and latent. HHV-8 generally enters the lytic cycle
immediately following primary infection, and then rapidly enters the latent phase. In the
latent phase, the viral genome assumes a circular conformation known as an episome. In
the latent phase, viral replication is suppressed, resulting in the formation of a quiescent
state of dormancy, with which minimal gene expression occurs. HHV-8 is able to
establish a predominantly latent, life-long infection in host monocytes, dendritic cells, B
lymphocytes, and endothelial cells.
As with EBV, infection of B cells by HHV-8 triggers the expression of several
latency-specific genes. These genes encode proteins that function primarily in the
maintenance of episomal viral genome in latently infected cells to transform the cells to
ensure the long-term survival in a short-lived cell. Latently expressed genes include
ORF71, which encodes a homologue of the antiapoptotic factor vFLIP, and ORF73, the
latent nuclear antigen (LANA) which functions to maintain genome integrity and
episomal persistence [25].
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Lytic phase of infection
For viral propagation to occur, the virus should undergo reactivation from the
latency into the lytic phase, when active viral replication occurs and newly synthesized
virions are released into the extracellular space. The herpesvirus lytic replicative phase
can be divided into four phases, immediate early (IE), early (E), partial late, and late,
depending on the transcription pattern prior or after lytic life cycle induction (reviewed
in[1]).
Immediate-early (IE) or α genes require no prior viral protein synthesis. These
genes are involved in transactivating transcription from other viral genes. The most
notable HHV-8 IE gene, ORF50 encodes R transcriptional activator (Rta), which
functions in the earliest phases of reactivation from latency into the lytic cycle [25].
Early or β genes, are expressed independently of viral DNA synthesis. Encoded
by K2, vIL-6 is a homolog to the cellular IL-6, and stimulates multiple cellular pathways
to induce cell proliferation, immunomodulation, and anti-apoptotic activity [26].
Polyadenylated nuclear (PAN) RNA stabilizes unspliced transcripts, increasing the
abundance of RNA in the nucleus and blocking the assembly of mRNA-protein
complexes [27].
Partial late or γ1 genes are expressed in concert with the beginning of viral DNA
synthesis. This is a subset of late genes, and their transcription rate is enhanced during
DNA synthesis. ORF18, which encodes a transfactor that is essential for late gene
transcription of gammaherpesviruses, is considered to be a γ1 gene [28].
Late or γ2 gene expression is totally dependent upon synthesis of viral DNA.
Virion structural genes encoding for capsid proteins and envelope glycoproteins are
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considered as late genes. K8.1 is a late gene that encodes a viral envelope glycoprotein at
a late phase of infection [29].
HHV-8 immune responses
Neutralizing antibody (nAb) responses against HHV-8 have been investigated in
several systems. A 2004 study compared levels of HHV-8 infection in dermal
microvascular endothelial cells after incubation with serum from HHV-8 seropositive
individuals, versus HHV-8 negative controls. Using an indirect immunofluorescence
assay, these investigators reported significant inhibition of HHV-8 by seropositive sera
diluted at 1:10 or 1:50, but not at 1:500. Depletion of the IgG fraction of the seropositive
sera by protein A resulted in a loss of the HHV-8 neutralizing activity [30].
Another group reported similar results using HHV-8 infectivity assays on293
cells, and also found that patients with KS had significantly lower nAb titers compared to
other HHV-8 infected groups, suggesting a possible role for nAb in protecting against
progression from latent HHV-8 infection to KS [31]. In contrast, Inoue et al. (2004)
found no significant difference in the levels of nAbs in HHV-8 positive individuals with
KS (24%) compared to those without KS (31%) [32].
Because of the association between HIV and HHV-8, several studies have
explored the question of whether CD4+ T cell levels influence immune responses to
HHV-8. Among HIV-infected individuals, Kimball et al. (2004) reported that those with
KS had lower CD4+ T cell counts and higher levels of anti-HHV-8 antibodies than those
without KS [31]. This suggests that HHV-8 replication may be limited by CD4+ T cell
activity. Another study similarly found that HHV-8 infected people with declining CD4+
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T cell counts were associated with increasing antibody reactivity against the HHV-8 Orf
65 minor capsid antigen [33].
HHV-8 infection also stimulates cytotoxic T lymphocyte (CTL) responses. A
1999 study demonstrated that seven out of seven HHV-8 positive, KS negative
individuals exhibited MHC class I-restricted CTL-activity against three HHV-8 antigen,
the K8.1 and K1 lytic proteins, and the K12 latent protein. In contrast, only two of six
HHV-8 positive individuals with KS had detectable CTL responses against these
antigens. In one patient, whose KS had resolved under HAART therapy, CTL activity
was restored [34]. In an investigation of HIV-negative subjects that seroconverted to
HHV-8, Wang et al. (2001) observed distinct CD8+, HLA class I restricted responses and
increases in the interferon-gamma (IFN-γ) response to at least three of five lytic HHV-8
antigens in each of the five subjects. They also observed that CTL reactivity declined
after several years, probably as HHV-8 entered a more latent state after primary infection
[35].
Immune modulation by HHV-8
As is the case for all herpesviruses, one of the major immune evasion strategies
used by HHV-8 is the establishment of latency, during which the majority of viral genes
are not expressed. This allows the virus to “hide” from most host immune mechanisms
during this part of its replication cycle. When the virus is in the lytic phase, however,
other active mechanisms of immune evasion take place. Of the 86 genes encoded by the
HHV-8 genome, at least 22 may have immunomodulatory effects [36].
As part of innate immunity, the complement system may play a role in early
defenses against HHV-8. The ORF4 gene of HHV-8 encodes a protein called KSHV
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complement-control protein (KCP), also called kaposica, which inhibits complement
activation by two separate mechanisms [37]. KCP accelerates the decay of the C3
convertase enzyme complex generated by the classical pathway of complement
activation, and it also acts as a cofactor for factor I-mediated inactivation of C3b and
C4b.
HHV-8-associated diseases, especially KS, are associated with alterations in
secretion of a variety of cytokines. An early component of innate immune responses to
viruses is the secretion of type I interferons (IFNs). Cellular responses to type I IFNs
involve the IFN-regulatory factor (IRF) family of transcription factors, which increases
expression of MHC class I molecules and activates NK cells. HHV-8 encodes four vIRF
genes with homology to cellular IRFs [23, 38]. These vIRF proteins (vIRF-1, -2, -3, and 4) generally inhibit the activities of various cellular IRFs, plus they may have other
immunomodulatory activities, such as suppression of the IFN-induced, double-stranded
RNA-activated protein kinase R (PKR) [39] and inhibition of Fas ligand (CD95L)
expression [40].
As mentioned earlier in this review, tegument proteins of herpesviruses can also
be involved in immunomodulation. An example of this is the HHV-8 ORF45 (tegument)
protein, which blocks phosphorylation and nuclear translocation of IRF-7 [41, 42]. The
introduction of the ORF45 protein into the cell as part of the virion ensures that it is
active at the very earliest phases of infection, when deregulating IRF-7. The inactivation
of cellular IRF-7 seems to be a key event in HHV-8 replication, as evidenced by the
observation that the HHV-8 replication and transcription activator (RTA) protein, which

12
regulates the switch between latency and lytic replication, also negatively regulates IRF-7
by targeting it for proteasome-mediated degradation [43].
HHV-8 also encodes a homologue of human IL-6. IL-6 is normally synthesized
by mononuclear phagocytes, vascular endothelial cells, and other cells in response to
microbial infection and to other cytokines. Binding of IL-6 to the IL-6 receptor can have
several effects, including the synthesis of acute-phase proteins, stimulation of B
lymphocytes, and upregulation of apoptotic antagonists such as BCL-XL [44]. In 1996,
Moore et al. reported the discovery of a HHV-8 homologue of IL-6 (vIL-6) which shares
25% identity with the human cytokine [45]. In some infected individuals, secretion of
vIL6 may contribute to HHV-8-associated MCD and perhaps PEL by promoting cell
survival, driving proliferation and preventing apoptosis [46].
Due to the central role of CTLs in eliminating virus-infected cells in an MHC
class I-dependent manner, a large number of viruses interfere with presentation of
cytosolic antigens by MHC class I molecules. This is especially true for viruses, such as
herpesviruses, that establish persistent or latent infections, [47]. HHV-8 encodes two
proteins named modulator of immune recognition 1 and 2 (MIR1 and MIR2) [48]. During
lytic replication, these proteins increase endocytosis of surface MHC class I molecules,
leading to their degradation in endolysosomes [49-51]. This mechanism differs from
other known viral inhibitors of MHC class I expression, which interfere with the
synthesis or assembly of MHC class I chains or retain them in the ER [47]. HHV-8 MIR2
also reduces surface expression of at least two key molecules involved in T cell function-B7-2 (CD86) and ICAM-1 (CD54). B7-2 is an important T cell costimulatory molecule
that expressed by antigen-presenting cells, and ICAM-1 is an intercellular adhesion
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molecule that interacts with LFA-1. Therefore, MIR2 not only inhibits the MHCdependent presentation of antigen to T cells, but also interferes with other cellular
interactions that are essential for proper T cell function [49].
A more recently described immune evasion strategy employed by HHV-8 is a
modification or reshaping of the host cell receptors for natural killer (NK) cells [24].
Natural killer cells are known for their ability to directly lyse infected cells and secretion
of cytokines which limit viral replication, therefore playing a key role in early control of
viral infections. Dupuy et al. (2012) described the capability of HHV-8 in decreasing
expression of NKp30 and NKp46, both which are cellular receptors responsible for
activating NK cells. Also demonstrated was a down-regulation of the inhibitory receptor
CD161. It has been suggested that the loss of this receptor might result in the
accumulation of a population of NK cells with a lower activation threshold, which could
lead to the elimination of activated dendritic cells, establishing a defective antiviral
adaptive response [24].
Epigenetics
Epigenetics refers to modifications of DNA that affect gene expression, with no
change in nucleotide sequence. Epigenetic influences on disease have become an
important area of study in understanding factors that play a critical role in disease
development. Transcription of a gene is controlled by local chromatin structure.
Epigenetic modifications to the chromatin structure, either by changes to histones, or the
DNA strand itself, can change gene expression. Epigenetic modifications mostly include
chromatin remodeling, histone acetylation, and DNA methlyation. These all induce
changes in gene expression that may persist even after removal of the initiating agent,
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creating the potential to influence the health of future generations. One of the most
notable studies of epigenetics and disease was completed by Kaati et al. (2002). They
found by examining paternal grandfathers who experience a shortage of food at a critical
time in their growth and development, presented a decreased risk of death from
cardiovascular disease or diabetes in their grandchildren [52]. These findings suggest
that diet can cause changes to genes that are inheritable and these alterations can affect
susceptibility to certain diseases.
Oncogenic viruses are known to cause epigenetic modification. An example of
DNA methylation and implication in oncogenesis is seen in EBV. The EBV latencyassociated virus gene products in B cells lead to epigenetic repression and CpG
methylation of the pro-apoptotic gene Bim, inhibiting tumor suppression [53]. HHV-8 is
considered to be an oncogenic virus, in which its ability to maintain latency is implicated
in its oncogenesis. Chromatin remodeling and demethylation of the HHV-8 lytic switch
gene Rta (ORF50) promoter, controls viral lytic phase entry; hyperacetylation of the
latent replication origin controls latent cycle replication [54]. This switch between latent
and lytic phases of HHV-8 infection leads to active viral replication, cellular
transformation, or oncogenesis. In most primary effusion lymphoma (PEL) cell lines,
HHV-8 is in the latent phase, but the lytic cycle can be induced by treatment with the
DNA methyltransferase inhibitor 5-Azacytidine (5-AzaC), the HDAC inhibitor sodium
butyrate (NaB), and the HAT inducer tetradecanoylphorbol acetate (TPA) [55, 56]. Chen
et al. (2001) also showed that treatment with 5-AzaC, and therefore demethylation of the
HHV-8 Orf50 promoter, caused lytic reactivation accompanied by IE, early, and late
gene expression [55]. Orf50/RTA expression may be activated by physiological
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conditions, such as hypoxia, or pharmaceutical agents, leading to viral replication and
disease pathogenesis [57, 58].
This reprogramming of host cell DNA has important implications not only for
understanding viral persistence and pathogenesis of herpesviral associated diseases, but
also has potential significance in epidemiology and transmission. In transmission studies,
this potential influence of epigenetics raises many questions. What are these changes,
and how does the environment play a role? When considering viral pathogenesis, it is
especially interesting to determine if the epigenetic influence on disease may also be an
influencing factor on risk of transmission.
Epigenetic initiators are not well defined, but in human disease, many different
environmental influences have been implicated as sufficient to initiate epigenetic
changes, such as stress, diet, hormones, toxins, ageing, and genetic influences [59]. All
of these influences may play a role in viral ability to infect, persist, and replicate, and
therefore help explain populations at risk for disease, as well as potentially transmission.
Pathogenic Mechanisms of HHV-8
HHV-8 is considered to be an oncogenic virus because of its involvement in
cancer related etiologies such as B-cell lymphomas, and Kaposi’s sarcoma (KS). Much
of the pathogenic mechanisms of HHV-8 has been learned from studying KS
development. The classic hallmark of KS tissue is the appearance of characteristic
spindle shaped cells. Early histochemistry and ultrastructural studies revealed that
proliferating KS spindle tumor cells are of endothelial origin, confirmed by more recent
use of genomic technologies [60, 61]. Circulating blood mononuclear and endothelial
“Progenitor cells” when infected with HHV-8 are reprogrammed to resemble lymphatic
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endothelium, which upregulates several lymphatic associated genes such as lymphatic
vessel endothelial receptor 1 (LYVE1) podoplanin, and vascular endothelial growth
factor receptor 3 (VEGFR3) [62] (reviewed in [61]).
Worldwide, HHV-8 seroprevalence far exceeds the incidence of KS. This
indicates that HHV-8 infection alone appears to be insufficient for the development of
KS, suggesting that other cofactors are involved in the causal association, such as
epigenetic initiators as discussed earlier, co-morbidities, or host immune suppression. Of
most significance, is the apparent reliance of KS progression on host immune dysfunction
and the local inflammatory milieu. HHV-8 encodes a variety of gene products, some
involved in cell survival processes such as transformation, proliferation, cell signaling,
antiapoptosis and angiogenesis, and involvement in immune modulation, including
cytokine production, and immune evasion [60, 63]. All these mechanisms may be
involved in the promotion of oncogenesis and viral persistence.
Diseases caused by HHV-8
HHV-8 was first identified in 1992 by Chang and Moore (1994) in a biopsy of an
endothelial tumor lesion from an AIDS patient [19]. HHV-8 has currently been
determined to be the causative agent in distinctive pathologies: Kaposi’s sarcoma (KS),
body cavity-based B-cell lymphoma (BCBL), primary effusion lymphoma (PEL), and
multicentric Castleman’s disease.
Kaposi’s Sarcoma
Kaposi’s sarcoma (KS) is an atypical form of cancer that develops in supportive
connective tissue such as cartilage, bone, fat, muscle, blood vessels, and fibrous tissue.
Histopathologically, the lesions are classified as endothelial neoplasms containing not
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only the primary neoplastic proliferating spindle-shaped cells of endothelial origin, but
also an abundance of extravasated erythrocytes and infiltrating inflammatory cells. KS
was first described in 1872 by the Hungarian dermatologist, Moritz Kohn Kaposi, as a
relatively uncommon tumor of very limited prevalence found almost exclusively in
elderly men of Italian or Eastern European Jewish ancestry [64]. Years later, another
epidemiological form was reported in young adult and prepubescent equatorial black
Africans. In 1969, a third form of KS was documented as associated with
immunosuppressant therapy. However, it was not until 1982 when a sudden increase in
the prevalence of KS cases, affecting a large variety of individuals who were not
previously associated with any known epidemiological cluster, that KS began to elicit
amplified concern in the medical community. This novel form of KS was much more
aggressive, with a clinical course often characterized as disseminating and fulminating.
Eventually it was linked to a disease model later denoted as acquired immunodeficiency
syndrome (AIDS).
These separate manifestations of KS tumors have been shown to be essentially
identical from the histopathological standpoint. However clinical symptoms, age and the
course of the disease are distinguishable from each other, leading to classifications
designated as classic, endemic, AIDS-associated, and iatrogenic.
Classic Kaposi’s Sarcoma
The terms classic, Mediterranean, and sporadic KS all refer to the same form of
KS. This is a rare cancer demonstrating ethno-geographical predominance in Eastern
Europe, and the Mediterranean region with high incidence in Italy, Turkey, Greece, and
Israel [65]. Classic KS historically has an ethno-geographical predominance in the
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Mediterranean region, with up to a 10-fold higher incidence than in the rest of Europe
and the United States (U.S.). In general, the average onset of the disease is between forty
to seventy years of age, predominantly occurring in men with sex ratios estimated to
range from 3:1 to 10:1 [61, 66]. Classic KS tumors are described as one or more
asymptomatic lesions that occur in the dermal layer of the skin and appear as either
brown, blue, purple, or red blotches or nodules. The lesions are usually localized to one
or both lower extremities and frequently involve the ankles and soles of feet, but mucosal
and visceral lesions may develop [61, 65]. Mortality rates for classic KS are low, and
although the skin lesions are normally disfiguring, they often are not disabling. Kaposi’s
sarcoma lesions can persist for ten to fifteen years, with indolent growth of primary
tumors and a gradual slow growth of additional lesions. Complications most commonly
seen include venous congestion and dependant pedal edema secondary to the slowing of
circulation caused by physical pressure from local tumor infiltration, and infiltration of
surrounding tissues and lymphatics [67].
In chronic cases, visceral lesions can develop in lymph nodes, along the
gastrointestinal tract, and in other organs. Generally, these lesions are asymptomatic,
most often discovered only at autopsy, although gastrointestinal bleeding can occur [67,
68].
Endemic Kaposi’s sarcoma
In some equatorial countries of Africa, KS has existed for several decades,
documented as early as 1953 as a relatively commonly occurring neoplasm in native
populations [69]. This form of KS is known as endemic KS, and reflects the KS disease
that exists in Africa, not associated with the HIV/AIDS epidemic. From 1968 to 1970,
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KS was associated with approximately 6.6% of all cancers seen in Ugandan males,
reflecting endemic KS incidence prior to the HIV epidemic [70]. The epidemiology
differs than that of classic KS in the population demographics. The median age of classic
KS is 65 years, but the median age of endemic KS is 40 years. The disease is also seen in
both children and adults, with a higher male to female ratio of 15:1 (reviewed in [71]).
Two forms of endemic KS have been described; a local aggressive form and a
more rare lymphadenopathic form. The local aggressive form is very aggressive,
characterized by granulating chancroid sores and a fungating tumor that can penetrate
from the skin to the underlying bone [72]. The lymphadenopathy form is less frequent,
and develops primarily in prepubescent children [63]. The generalized lymphatic
involvement in the lymphadenopathic form is usually associated with visceral organs, and
is very aggressive [61]. In these cases, a 100% fatality rate within three years of
diagnosis has been reported [73].
Transplant-Immunosuppressive Therapy-Related Kaposi’s sarcoma
Kaposi’s sarcoma that develops due to the immunosuppressive therapy prescribed
for post-transplant patients to prevent graft rejection is referred to as immunosuppressionassociated or iatrogenic KS. Post-transplant KS can result in rejection of the graft and
death of the patient [26]. Penn et al. conducted a study of 356 pot-transplant patients
with KS. Of these 40% had visceral involvement and 17% of these died due to KS [26].
The risk of KS associated with transplants is exemplified by iatrogenic KS
prevalence rates of 500 to 1,000-fold higher in solid-organ transplant recipients than in
the general population, with 46% of all cases developing in the first year [74, 75]. Risk
varies geographically, ranging from 0.4% of transplant patients in the U.S. and Western
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Europe, to 5.3% of renal transplant patients in Saudi Arabia [26, 76]. This ethnogeographic variation reflects the HHV-8 seroprevalance in the general population of
different countries [26].
Iatrogenic KS appears more frequently in renal transplant patients as compared to
other grafted organs (reviewed in [1]). Presumably this is due to the types of drugs used
frequently in kidney transplant patients, including cyclosporine, which was demonstrated
to reactivate HHV-8 in vitro [77, 78]. The influence of cyclosporine was demonstrated in
a study in which eight of eleven iatrogenic KS patients had complete regression of
visceral and cutaneous tumor progression within six months of cessation of cyclosporine
[79].
AIDS-Related Epidemic Kaposi’s sarcoma
The beginning of the AIDS epidemic was ushered in by the appearance of a
fulminant and disseminated form of KS, first observed in U.S. immuno-compromised
homosexual males in 1981 [80-82]. Subsequently, KS became the most common
neoplasm occurring in patients with AIDS [77].
The underlying cause of AIDS was determined in 1985, originally named the T
cell leukemia type III virus, later to be renamed the human immunodeficiency virus
(HIV) [83-85]. HIV infects CD4 + cells, leading to cell death. The resulting immune
dysregulation results in an immune-compromised state that predisposes the host to a
variety of opportunistic infections and neoplasms, including KS.
AIDS-KS is a much more aggressive tumor than the other forms of KS and can
disseminate into the viscera with higher mortality rates [86]. The aggressive nature of
AIDS-KS has been hypothesized to be due to the HIV encoded protein, Tat. Tat is a
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transactivator of HIV viral genes, and also some host cell genes. Tat can act
extracellularly, inducing angiogenesis and inflammation in endothelial cells, contributing
to KS pathogenesis (reviewed in [87]).
As with the other forms of KS, AIDS-KS has different associated risks among
HIV positive individuals. In Western countries including the U.S., AIDS-KS
predominantly is found in HIV positive homosexual or bisexual men, and less commonly
in heterosexual individuals [77]. Studies in the U.S. have shown that HIV-infected
homosexual men have a greater than 10,000 times risk of developing KS than the general
population [88].
The impact of the AIDS epidemic on incidence rates of KS in African countries
has been significant. The increase in incidence does not exhibit the same gender and
sexual orientation preference exhibited in developed countries, with increased incidence
rates in both men, and women, as well as in children. In Uganda, KS accounted for
approximately 6.6% of all cancers prior to the onset of the AIDS epidemic; however data
compiled from 1981-91 attributed 48.6% of all cancers in males, making it the leading
cancer in males. In women, during this same time period, KS was the second most
frequent cancer, at 17.9%. In children KS increased by an additional 40% [70]. AIDSrelated KS risk associations in Africa include better education, an affluent life style,
urban as opposed to rural living, travel away from home, and co-infections with sexually
transmitted diseases [89].
By the mid 1990’s, the incidence of AIDS-KS in HIV positive individuals
decreased significantly due to the introduction of highly active antiretroviral therapy
(HAART) [90, 91]. HAART represents the use of a combination of antiretroviral
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pharmaceutical therapies, sometimes termed a drug cocktail. It combines protease
inhibitors with reverse transcriptase inhibitors, which helps to prevent the emergence of
drug-resistant HIV strains and decrease viral load. The success of HAART results in
increased T-lymphocyte survival, decreased patient mortality rates, and a reduction in
AIDS defining diseases such as KS. In a study done on 14,183 people diagnosed with
AIDS during 1990-2000 in San Francisco, CA, factors associated with a longer KS
survival time included HAART use for 6 or more months (HR=0.37, 95% CI 0.31-0.45)
[92].
Transmission of HHV8
Transmission of HHV-8 in adults has been suggested to occur via blood, bodily
fluids, and sexual contact. In industrialized countries, sexual transmission is highest in
the population of men who have sex with men (MSM). A study conducted on a San
Francisco cohort of MSM, HHV-8 found significant rates of sexual transmission [93].
Engels et al (2007) in a study using the NHANES III cohort examined HHV-8 status on
13,894 adults over 18 years of age for associated risk factors. Their findings showed that
among MSM seroprevalence increases with the number of previous male partners, and an
association exists with HHV-8 seropositivity and duration of heterosexual activity and
lifetime number of heterosexual partners. However, no associations with sexual risk
factors were found among women [94]. In contrast, a cohort in Zimbabwe of
heterosexual men found that HHV-8 infection was not associated with any sexual risk
factors other than with HIV-1 infection [95]. Taken together, these studies suggest that
sexual transmission may occur, but is more likely to occur in MSM rather than
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heterosexual sexual contact. Sexual transmission does not explain the high prevalence of
HHV-8 in endemic populations, and does not explain the risk of transmission to children.
Blood and blood products have been explored as a potential route of transmission.
Occurrence of HHV-8 transmission in intravenous drug users gives evidence that
transmission via blood is possible [96-98]. Disparity among several studies suggests that
transmission of HHV-8 via transfusion of blood or blood products is possible, but
unlikely [99-101]. The reports of transmission via blood transfusion products vary
greatly with geographical area. Incidence rates are low in North America, and higher in
areas of endemic HHV-8. A Ugandan study demonstrated that 41 of 991 blood
transfusion recipients seroconverted to be HHV-8 positive post transfusion, with an
increase in risk noted in those receiving HHV-8 seropositive blood [102]. It is likely that
the risk varies not only with population prevalence, but also with the differences in
collection and storage of blood products. Such studies are difficult to conduct due to the
co-morbidities of transfusion recipients that may bias results, as well as the anonymous
nature of the blood donation, making it difficult to follow-up to confirm serodiagnostic
tests.
In children, there is a paucity of data regarding when and how transmission
occurs. HHV-8 has been shown to productively infect placental cells in vitro, confirming
the possibility of mother to child vertical transmission [103]. In addition, epidemiologic
studies have shown HHV-8 transmission from mother to child vertically during
pregnancy, but the incidence is found to be low [104, 105]. The increase in the
prevalence of HHV-8 throughout early childhood prior to onset of sexual activity
suggests the possibility of additional routes of transmission via mother to child routes,
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most likely during early childhood [106-108], or between household contacts and among
children, possibly via saliva [109-111]. Another source to consider is breast milk.
Although breast milk is known to transmit other viruses such as CMV and HIV-1,
previous research indicates a lack of HHV-8 DNA in breast milk, making transmission
unlikely [112].
Saliva has also been implicated in the transmission of other human herpesvirus
family members, including HSV-1, HHV-6, and HHV-7 [113-115]. Our lab has
previously isolated, HHV-8 virus in saliva samples from seropositive mothers implicating
saliva as a likely mode of HHV-8 transmission [116]. Other published studies have also
indicated saliva as a mode of transmission. A South African study found that an
increased prevalence of HHV-8 specific antibodies in children in mothers shedding >5 X
104 viral DNA copies/ml of saliva, which suggests that l high viral load in saliva may be
associated with transmission to the child [106].
In examining HIV status as a risk factor for transmission of HHV-8, Miller et al.
demonstrated that HIV-positive individuals were significantly more likely to shed HHV-8
in their saliva than the uninfected controls (OR, 4.15 [95% CI, 1.87 to 9.19]) [117]. In
the United States, saliva has been implicated as a source for transmission of HHV-8 in
HIV positive individuals, because viral DNA has been detected in as many as 70% of oral
cavity samples in studies involving HIV-1 infected men with KS [118]. However, our
lab found no significant difference in HHV-8 viral shedding in saliva cells when
comparing HIV-1 infected mothers and uninfected mothers in a mother/infant cohort
from Lusaka Zambia [112]. HHV-8 infection in children was not found to be associated
with either HHV-8 or HIV-1 infection of the mother [119], however we found while
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following the same cohort longitudinally, that childhood HIV-1 status was a significant
risk factor for the child to acquire HHV-8 infection by 48 months of age (HR, 4.60
[95%CI, 2.93,7.22]) [120].
An interesting area of study in the epidemiology of infectious diseases is genetic
risk. A study in Sardinia identified an HLA predisposition in classic KS patients,
identifying a positive association with types HLA-DRB1*1104, DRB1*1302,
DQB1*0302, Cw7, and DQB1*0604 and a negative association with types A30, B58,
Cw5, DRB1*1601, and DQB1*0502 [121]. A positive association was identified with
AIDS-KS and a critical amino acid residue at position 13 in HLA-DRB1 [122]. These
studies taken together with HHV-8 association with KS, has prompted studies into the
genetic influence on HHV-8. In a South African study, Alkharsah et al. (2007) found a
significant association with allele groups HLA-1*68, HLA-1*43, and HLA-DRB1*04
with an increased rate of viral shedding or increased viral load in a cohort of HHV-8
infected mothers [123]. However, a Ugandan group did not find any associations with
types HLA-A and HLA-DRB1 alleles, and only with children with the HLA-B allele.
They found a marginal association of KSHV DNA shedding in saliva but not in
peripheral blood among children carrying HLA- B*4415 and marginal association of
KSHV DNA shedding in peripheral blood but not in saliva among children carrying
HLA- B*0801 alleles. This suggests that different populations could pose different
genetic risks, however small sample size could bias their data [124]. Further longitudinal
studies are needed to confirm the influence of haplotypes in increased risk of HHV-8 in
populations and the subsequent transmission to susceptible children.
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Whitby et al. (2007) proposed that environmental cofactors present in KS
endemic regions are responsible for reactivation of HHV-8 in infected subjects, leading
to high viral loads, increased viral shedding, and an increased risk of transmission.
Dubbed the “oncoweed” hypothesis, this study presents in vitro data demonstrating an
increased expression of KSHV mRNAs upon exposure to extracts from African native
plants. Several of these plants are used in native populations in activities such as basket
weaving or in traditional medicine [81]. This data suggests a possible role of
environmental factors as an originator of epigenetic changes, leading to increased viral
replication and an increased risk of transmission.
HHV-8 Diagnostics
Polymerase chain reaction (PCR)-based methodology of HHV-8 DNA detection
gives the greatest specificity for diagnosis, compared to all other tests currently used for
measuring HHV-8 exposure or infection. Viral genomic copy number varies according to
cell type and disease status. For example, chemically infected B lymphoma cells carry
40-150 copies of HHV-8 DNA per cell genome, compared to 1-2 copies per cell in KS
tissue. In terms of other body locations, viral DNA is most often found in saliva followed
by peripheral blood mononuclear cells (PBMC) and occasionally in semen and the male
urogenital tract.
In PEL cells, also referred to as body cavity-based lymphoma cells (BCBL),
HHV-8 DNA is detected at 100% efficiency, which corresponds to 100% assay
sensitivity. In comparison, PCR of KS lesions from known HHV-8 positive patients is
detected in approximately 95% of all cases. This discrepancy between BCBLs and KS
tissues is believed to reflect the viral copy number as well as cellular heterogeneity of the
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tissue opposed to the relative homogeneity of the single B-cell typed lymphoma. In
circulating PBMCs and in the plasma, detection of HHV-8 DNA in seropositive
individuals is very rare, possibly because of low levels of viral replication during latent
infection. Viral DNA detection has been used to analyze HHV-8 disease-associated
progression. Reactivation of latent virus and proliferative infection leads to an increase in
viral load in the peripheral blood stream. This increased viral load contributes to
increased viral dissemination and spreading of the infection. In KS patients, an increase
in plasma viral DNA, isolated from other blood products including not lysed cells, has
been used as an indicator of a more advanced viral infection. Studies have also
demonstrated a strong correlation between viral load within the peripheral blood,
including cells, and an increased risk of KS progression. Hence, peripheral blood viral
load is used to predict the pathogenic outcome of the infection by measuring active HHV8 replication through PCR detection of viral DNA.
The low sensitivity and expense of the method limit the clinical application of
viral DNA detection in population screening. Immunologic assays are the most widely
used in HHV-8 diagnostics. Currently four antibody detection assays are commonly used
in HHV-8 serodiagnostics: enzyme-linked immunosorbant assay (ELISA),
immunofluorescent assay (IFA), Western blot, and immunohistochemistry (IHC).
Immunofluorescence assays (IFAs) are used extensively in serodiagnostics. This
technique employs a target cell expressing desired viral proteins fixed and spotted onto
glass slides. If antibodies specific for the expressed proteins are present in the patient’s
plasma, those will attach to the antigen, indicating past or present patient exposure to the
virus. A detection antibody is then applied, usually a commercially available antispecies
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(i.e. human) antibody with a fluorescent tag. The slides can then be viewed with
fluorescent microscopy to identify seropositive patients. Target cells used in this assay
are often B-cell lymphoma based cells, stimulated to express lytic phase proteins using
either sodium butyrate [125], or12-O- tetradecanoylphorbol-13- acetate [126]. Antibodies
recognizing lytic proteins will result in a whole cell fluorescent staining, whereas
recognitions of latent proteins results in a more restricted, punctate nuclear appearance,
demonstrating recognition of the latently expressed protein, LANA.
Also commonly used in IFAs are recombinant proteins expressed in insect cells.
As discussed in later in chapter 5, Spodoptera frugiperda (Sf9) are cells that can be used
for recombinant protein production using baculovirus expressing immunogenic proteins
such as K8.1, LANA, and ORF65 [126].
HHV-8 in Zambia
In sub-Saharan Africa there has been an increase in KS co-incidental with the
HIV epidemic and high incidence of HHV-8 infection, with seroprevalence reported to
range from 20-48% [127, 128]. KS is known to be the most common tumor among HIV
positive individuals [129].
A dramatic increase in incidence of KS was observed after the HIV epidemic. In
children, KS was relatively rare prior to 1980, but by 1990 to 1992, post the emergence
of the HIV epidemic, the incidence in children raise to constitute 20-25% of all pediatric
malignancies in Zambia [130]. In this same study, pediatric KS incidence noted at the
University Teaching Hospital in Lusaka, Zambia increased from 3.2% to 19% in just one
decade [130].
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Preliminary data from our laboratory has determined HHV-8 seroprevalence rate
of Zambian children at 12, 24, 36, and 48 months of age as 15%, 20%, 18%, and 22%
respectively [120]. While in utero HHV-8 infection is possible, it cannot account for the
high HHV-8 seropositivity in children during the first 12 months of age. These findings
suggest that horizontal transmission is likely the predominant mode of virus transmission
in our targeted study population. The overall goal of my dissertation research is to
delineate possible routes and risk factors of HHV-8 transmission within a household to a
susceptible child. Although breastfeeding has been implicated in early transmission of
other viral diseases such as HIV our previous research has demonstrated that HHV-8
DNA cannot be readily detected in breast milk. However, HHV-8 virus can be isolated in
saliva samples obtained from seropositive mothers in our above defined cohort,
implicating saliva as a likely mode of HHV-8 transmission to children, but the maternal
serostatus of HHV-8 is not a significant risk factor in transmission [112].
STUDY AIMS
The hypothesis of this dissertation research is that children in Sub-Saharan Africa
can be infected by HHV-8 in early childhood through saliva contact with household
members. This research plan was designed to test this hypothesis. To test our
hypothesis, three specific aims were pursued, they are:
1. To determine risk factors associating with HHV-8 positive children as compared
to negative children
a. Evaluating questionnaires specific to eating, feeding, and social practices
within households.
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b. Identifying significant behaviors or factors specific to either HHV-8
positive or negative household members.
c. Identifying health status associations such as child nutritional status or
other co-infections as risk factors for HHV-8 infection.
d. Completing statistical analysis to look for significant difference.
2. Following the child for seroconversion post-enrollment in the study.
a. Evaluating the uninfected child every four months to determine incidence
of HHV-8 seroconversion.
3. Determining the risk factors associated with the household and the child during
seroconversion.
a. Assessing if HHV-8 positive households increase the risk of
seroconversion of the index child
b. Assessing lifestyle habits or behaviors that increase exposure to saliva,
blood or bodily fluids through extensive questionnaires.
c. Identifying potential factors that could be of interest
B. Socioeconomic factors
C. Demographic data
D. Co-infections
d. Completing statistical analysis to look for significant difference.
In chapter 2, The Zambia Children’s KS-HHV-8 Study is described in detail. The
study design, recruitment, enrollment and cohort description is presented. Potentials for
bias are addressed, and the socio-demographics of the enrolled cohort are described.
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In chapter 3, specific aim 1 is met. A baseline cross-sectional analysis is
performed, examining 75 HHV-8 positive children that were enrolled into the study.
Caregiver and household behaviors, health practices and child health status were
analyzed. HHV-8 presences in the household as well as behaviors such as testing the
temperature of food prior to feeding to a child were determined to be significant risks of
HHV-8 seropositivity.
In chapter 4, specific aims 2 and 3 are met. The children enrolled in the Zambia
Children’s KS-HHV-8 Study are followed for the duration of 48 months. Incidence rates
are calculated, and risk analysis is completed. This prospective cohort study supports the
findings of the first study in significant risks associated with saliva sharing behaviors and
childhood acquisition of HHV-8.
Also included in this dissertation in chapter 5 is a study that was completed in
analytical methods. To complete the serodiagnostics of the children and household
members, a reliable assay is required. No gold standard exists for testing for HHV-8
infection. This final chapter outlines the work that was done prior to the beginning of the
Zambia Children’s KS-HHV-8 study, and helps to exemplify some of the work involved
in assay development.
Overall, this dissertation describes the development of an epidemiologic study to
examine HHV-8 transmission within households, and the association of transmission of
HHV-8 to a susceptible child with behaviors that expose a child to saliva. Taken together,
they describe epidemiologic, diagnostic, and analytical methods used in the investigation
of risks associated with early childhood HHV-8 acquisition.
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TABLES
Table 1. Human Herpesvirus Subfamilies, Associated Diseases in Humans, Cellular
Tropism and Means of Transmission Among Humans.

Virus name
Herpes simplex
virus Type I
(HSV-1)
Herpes simplex
virus Type 2
(HSV-2)
Varicella Zoster
Virus (VZV)
(HHV-3)

Subfamily

Cellular
tropism

α

Oral herpes-Cold Sensory Nerve
sores
Ganglia

α

Genital herpes

Sensory Nerve
Ganglia

α

Chicken-pox,
shingles

Sensory Nerve
Ganglia

Epstein Barr
virus (EBV)
(HHV-4)

γ

Cytomegalovirus
(CMV) (HHV-5)

β

Roseolovirus
(HHV-6A)
Herpes
lymphotropic
virus (HHV-6B)

β

Human herpes
virus-7 (HHV-7)
Human herpes
virus-8 (HHV-8)

Major
associated
disease in
humans

Burkitt’s
lymphoma
nasal pharyngeal
carcinoma
Infectious
mononucleosis
Congenital
disease resulting
in hearing loss

Means of
Transmission
Oral routes,
sexual
Sexual
transmission
Respiratory and
sexual

Saliva,
transfusions,
B lymphocytes
tissue
epithelial cells
transplant, and
congenital
CD4+ T
lymphocytes

Saliva, urine,
breast milk

Exanthema
subitum (roseola
infantum)

CD4+ T
lymphocytes

Respiratory,
congenital
mother to child

β

Exanthema
subitum (roseola
infantum)

CD4+ T
lymphocytes

Unclear, likely
saliva

γ

Kaposi’s
sarcoma

B lymphocytes
Sexual, saliva,
Endothelial
rare congenital
cells
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ABSTRACT
The HIV epidemic in Zambia has led to a dramatic rise in the incidence of human
herpesvirus 8 (HHV-8) -associated Kaposi’s sarcoma in both adults and children. But
there is a paucity of knowledge about the routes of HHV-8 transmission to young
children. The Zambia Children’s KS-HHV8 Study; a large prospective cohort study in
Lusaka, Zambia was launched in 2004 to investigate the role of household members as a
source of HHV-8 infection in young children and social behaviors that may modify the
risk of HHV-8 acquisition. This cohort is distinct from other epidemiological studies
designed to investigate HHV-8 incidence and transmission because it recruited and
followed complete households in the urban Central African context. Between July 2004
to March 2007, 1,600 households were screened and 368 households comprising 464
children and 1,335 caregivers and household members were enrolled. Follow-up of this
population has continued for 48 months post-recruitment, affording a unique opportunity
to study horizontal transmission of HHV-8 and understand the routes and sources of
transmission to young children in Zambia. We describe the study rationale, design,
execution and characteristics of this cohort which provides critical data on the
epidemiology and transmission of HHV-8 to young children in Zambia.
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INTRODUCTION
Human herpesvirus-8 (HHV-8), also known as Kaposi’s sarcoma-associated
herpesvirus (KSHV), is the most recently described human herpesvirus [1]. With the
emergence of the HIV epidemic, Kaposi’s sarcoma (KS) has become one of the most
frequently diagnosed cancers in sub-Saharan Africa [2]. The seroprevalence of HHV-8
varies greatly and is generally high in areas where classic or endemic form of KS is
common [3]. One such country is Zambia, a part of the “KS belt” where endemic KS was
prevalent and where significant increase in KS incidence in adults and children has
coincided with the emergence of the HIV-1 epidemic [4-6]. By 1992, KS accounted for
approximately 25% of all childhood cancers diagnosed in Lusaka, the capital of Zambia
[7].
Routes of HHV-8 transmission and factors associated with increased risk of
HHV-8 acquisition have yet to be delineated. Based on results from our previous cohort
study in Zambia conducted from 1998 to 2003, we were the first to report that; 1) HHV-8
may be transmitted perinatally albeit rarely; 2) HHV-8 may be detected in saliva but not
in breast milk, and; 3) early childhood infection with HHV-8 is common [8-10]. Taken
together, these results suggest that the major mode of HHV-8 transmission to children is
by person-to-person contact, likely via saliva. We have also reported that HHV-8
infection in young children could occur independently of the HHV-8 serostatus of the
mother, suggesting the possible role of other household members in transmitting infection
[10]. Therefore it is critical to evaluate the role of household contacts in transmitting
infection to young children especially in HHV-8 endemic areas like Zambia. To date,
there has been no cohort study designed to recruit and follow entire households to
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investigate HHV-8 transmission within households. Socioeconomic factors such as low
parental education, using water from a communal source and low income have been
implicated as risk factors associated with HHV-8 seroprevalence; these studies were
cross-sectional in design and thus unable to associate specific risk factors with incident
HHV-8 infection [11-13]. Therefore, the Zambia Children’s KS-HHV8 study was
designed in which longitudinal 4 year follow-up of recruited households was undertaken
with the specific objective of determining the rate and source of horizontal transmission
of HHV-8 to young children. We aimed to investigate whether transmission of HHV-8 to
young children could occur through casual, person-to-person contact within a household.
Conducting prospective cohort studies are challenging endeavors, particularly in
resource poor settings such as Zambia, which has poor infrastructure, high poverty levels,
and limited number of skilled personnel. The aim of this report is to describe the
rationale, design, execution, logistics and characteristics of a large observational
household-based cohort study in Lusaka, Zambia.
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MATERIALS AND METHODS
Study population and site
The Zambia Children’s KS-HHV8 study is a community-based cohort study
executed by investigators of the University of Zambia Teaching Hospital (UTH) in
Lusaka, Zambia in collaboration with investigators at University of Nebraska Lincoln.
The study coordinating office was based at the UTH, with an independent clinic for
recruitment and follow-up of study participants and a fully equipped laboratory for
biospecimen processing, testing, and storage. The study office also houses the data
management team and the study coordinator; together they manage the paper and
electronic versions of questionnaires, study- related forms and laboratory results. All
study personnel at the clinic and laboratory are Zambians and all study related
discussions and decisions are made by consensus by the study coordinator, Zambian and
U.S.-based study directors and the principal investigators. This study was approved by
the Institutional Review Board at the University of Nebraska-Lincoln and the Ethics
Board of The University of Zambia.
Screening for enrollment
Recruitment and long-term follow-up of participants in Zambia can be a difficult
process. There is general disinterest concerning participation in research studies as the
economic and educational status of an average household is low, with approximately
64% of Zambian households living below poverty (in 2006) [14]. Zambia is one of the
poorest countries in sub-Saharan Africa with a large percentage of a highly mobile
population living in unorganized and densely populated settlements called ‘compounds’,
making it difficult to locate and track study participants. To achieve a high follow-up
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rate, we tried a novel method to create interest in the study and encourage follow-up
visits. Community health workers (CHW), who were trained and educated about the
study goals, spread the information about the goals of the study in their community.
CHWs were residents of Lusaka and were instructed to reach potential study participants
not only from within their residential areas and clinics but also from areas and clinics in
other compounds. CHWs provided potential study participants with the basic information
about the study goals and expectations, and gave opportunity to ask questions. If
interested, they were directed to visit the study office at UTH, where trained study nurses
provided comprehensive information about the study and answered all relevant questions.
HIV and HHV-8 counseling was also given and written informed consent was obtained to
participate in the study. Upon obtaining consent, each household and each member of the
household was given a unique identification number. Participation incentives included
the availability of basic health care at the study clinic, counseling to all study participants,
common medications at no cost and reimbursement of the travel cost to the study office
and clinic.
Our objective was to enroll complete households that had at least one HHV-8
negative child (referred to as index child). The eligibility criteria were 1) having an
HHV-8 negative index child between 6 and 24 months of age in a household (children
younger than 24 months were screened for HHV-8 serostatus); 2) the household had to
reside in Lusaka District. Our early research experience suggested that participants living
outside Lusaka were difficult to recruit or follow-up because of their inability or
disinterest in travelling to the study site at UTH. According to the 2000 census, 14% of
the Zambian population lived in Lusaka District, we therefore decided to limit to study
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participants residing in Lusaka District [15]; 3) all members of the household, up to a
total of 10 members, had to agree to participate and visit the study office for scheduled
follow-up visits. The size of the household was limited to 10 to help limit the number of
possible contacts with the index child; 4) the child should not be seriously ill (for
example, Tuberculosis, cancer, AIDS) on the day of screening to ensure timely follow-up
visits. Seriously ill children were excluded only because of their inability to travel or
health risks involved in travelling to the study clinic. On meeting all the eligibility
criteria, all members of the household had to return to the study office for enrollment
within one month of screening. In addition a small group (n=32) of HHV-8 positive
children younger than 24 months of age were enrolled as a control group to investigate
the risk factors for seroconversion for a baseline cross-sectional analysis.
Enrollment and follow-up
The HHV-8 negative children along with their primary caregiver were requested
to return for follow-up visits every 4 months until age 48 months; the other household
members were followed annually. During each visit, all the study participants received a
physical exam and free medications for common ailments such as worm infestation, fever
and minor aches and pains, and multivitamin supplements in case of malnourishment.
During enrollment and at each follow up visit, various biologic specimens were collected
as described in the next section, health assessments were completed, and questionnaires
to obtain demographic and behavioral information were administered (Table 1).
Throughout the duration of the study, increase in household size due to additions in the
household were enrolled either as index children if under the age of two years, or as
household members if older than two years. CHWs tracked study participants that did not

51
return for scheduled visits to remind them of their missed visits or, if they decided to
withdraw, determine the withdrawal reasons.
The major outcome variable of interest was HHV-8 serostatus at each visit.
Outcome assessment was done by testing plasma collected from each infant during each
follow up visit for evidence of HHV-8 infection as described previously [16]. HHV-8
shedding in buccal cavity was also monitored at each visit.
Data collection instruments and exposure assessment
Structured interview questionnaires were developed to collect information on
factors that may be associated with increased risk of horizontal transmission of HHV-8 to
the index child. The content of these questionnaires were based on discussions with focus
groups conducted in March 2004 [17]. Discussions with men and women from diverse
ethnic and socioeconomic backgrounds were conducted to determine various behavioral
and socio-cultural practices that could impact the risk of the index child acquiring HHV8. The questionnaires were administered to the caregiver during enrollment and at each
follow-up visit in English or the local language (translated into commonly used
languages, Bemba or Nyanja, by the interviewer). Questions pertained to household
living conditions (electricity, water source, toilet facilities, number of rooms/sleeping
areas, household density), behaviors involving food and drinks (premastication, sharing
sweets and/or drinks), health and personal care practices (example, bathing habits, use of
traditional medicine and the use of saliva to soothe injuries), demographic variables (sex,
age, education of the primary caregiver, household size, playmates), medical history
(ailments and hospitalizations) and health assessments of the primary caregiver and the
child. Developmental milestones of the child were also recorded.
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Data management
Printed copies of the questionnaires and laboratory test results were recorded in
the database and managed locally. Databases were generated by entering each form twice
and comparing both entries to identify entry errors. At the initiation of the study we
employed an optical character recognition software for transferring information from
each form to the database. However, character recognition and record posting problems
were frequently encountered leading to extensive manual data cleaning. Subsequently,
manual entry using MS Access™ forms was employed leading to significant
improvement in data quality. Copies of the database were regularly provided to the study
staff at University of Nebraska-Lincoln where analytic datasets were generated and are
currently being used for analysis, review and publication by study investigators.
Biospecimen collection and processing
All samples collected at the clinic were processed by the study laboratory within
two hours of collection. Venous blood was collected from all the study participants at
every visit and plasma was separated and stored. The peripheral blood mononuclear cell
(PBMC) pellet was divided in two vials; one vial was stored at -80 ⁰C and the other vial
was lysed for DNA extraction. During the screening visit, both the child and the caregiver
were tested for presence of HHV-8 and HIV-1 antibodies as described previously [16].
Screening for the presence of HIV-1 antibodies was done using Abbott Determine
(Abbott Laboratories, Chicago, USA) and confirmed using Unigold (Trinity Biotech,
Ireland) test kits, according to Zambia Ministry of Health, HIV-1 testing guidelines. For
children younger than 18 months of age, polymerase chain reaction (PCR) was performed
in the study laboratory using dried blood spots. Buccal cells were also collected at each
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visit by scraping the buccal cavity with a cotton swab, then stored in a collection tube
containing cell lysis buffer until DNA was extracted. Buccal cell lysates were used for
investigating HHV-8 shedding, frequency of shedding, and the viral load present in the
oral cavity.
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RESULTS
From July 2004 to March 2007, caregivers from 1,600 Zambian households,
including 1,657 index children younger than 24 months (referred to as index child)
visited the study clinic for participation in the study. All were residents of one of 40
townships within Lusaka District (Figure 1). While our attempt was to achieve sampling
from all areas of the city, we were unable to sample equally from all residential areas
especially areas with residents from higher socioeconomic status. Our goal was to recruit
and retain at least 370 index children to have 85% power to detect HHV-8 seroconversion
difference from 0.12 to 0.22 at a significance level of 0.05. By the end of the study period
there were 464 index children and 1,335 household members enrolled (Figure 2).
During the first visit to the clinic, eligibility was determined after the caregiver
provided informed consent to participate in the study. Refusal to participate at this visit
was rare (0.5%) because caregivers had a basic understanding about the study through
CHWs before they attended the study clinic. The most common reason for refusal was
fear of blood collection. Eligibility criteria were met by participants of 1,023 households
who were invited to return with the entire household within one month (Figure 2). Of
these, all members of 368 households (1,799 total study participants) were enrolled and
followed. In 254 households, one or more household member(s) could not attend the
study clinic within the specified enrollment period, were considered incomplete
households and not followed at later time points. The enrollment rate of complete
households per households initially screened was 23.0%. There was variation noted in
enrollment rates between townships (P <0.0001), most likely as a result of distance and
accessibility to the study site (data not shown).
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The annual enrollment and characteristics of 464 index children and 1,335
household members during the enrollment period are summarized in Table 2. Of the 464
index children initially enrolled, 395 children (85%) returned for one or more visits. The
baseline characteristics of the 368 enrolled complete households are summarized in Table
3. Homes were generally small in size (mean - 2 rooms), with mean of 4.7 household
members per household. A majority of the households were of lower socioeconomic
status having no electricity, running water or in-home toilet.
Table 4 summarizes the characteristics of the primary caregiver, and his/her
relationship with the enrolled index child. There were a number of different household
structures represented, including multiple index children in a single household. The
second index child could be a younger sibling, a niece, nephew, or other extended family
member living in the household. Of the 464 enrolled index children from 368 households,
97% of caregivers were mothers to these children, while others included grandmothers,
aunts, father and even cousins. A majority of primary caregivers were between 20-29
years of age (54.3%, age range - 14 to 78). Households were classified as ‘two parent’ if
both a mother and a father to at least one index child in the household were present,
‘single parent’ if only one parent was available in the household (all the single parents in
our enrolled cohort were mothers), and if there were no parents, or if the household
included another adult such as an aunt or uncle, these households were classified as
‘extended family’. Nearly half (48%) of the households were classified as either ‘single
parent’, or ‘extended family’, which reflects a community continuing to suffer a high
adult mortality rate from HIV/AIDS and related conditions. Most of the primary
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caregivers in the cohort (54%) had completed primary education; no primary caregiver
reported education beyond high school.
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DISCUSSION
In this report we describe the study rationale, design, and methods of the Zambia
Children’s KS-HHV8 study in Lusaka, Zambia. This study is the only known study that
has recruited and followed complete households, in an HIV/AIDS and KS endemic area
like Zambia. Our objective was to design and implement a study to examine HHV-8
incidence and factors associated with HHV-8 acquisition by young children. Collection
of a wide range of demographic, medical and behavioral data and biological samples
during each visit have enabled us to meet our objectives.
Several steps implemented in this study ensured its success in recruitment and
follow-up. This is a second cohort study being undertaken by our group. The present
study allowed us to establish a fully equipped, modern diagnostic laboratory within the
premises of UTH which provided no-cost service to UTH patients, helping build positive
relationships with local health officials. Additionally, the establishment of the study
clinic helped to provide basic medical care to study participants who seldom have access
to quality medical care, encouraging participation and high follow-up rates. The study
emphasized the follow-up of children for childhood health and wellness, prevention, of
common childhood illnesses, with regular household checkups having a focus on the
well-being of the child, rather than only emphasizing the testing for HIV-1 infection. This
was done to increase participation rates because some households are not eager to
participate in HIV-1 studies as compared to studies emphasizing the general well-being
of the child. Close collaboration with local CHWs was of immense help during screening
and recruitment of households as education level is low in most communities in Lusaka,
which made it difficult to spread the correct message regarding the objectives of the
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study. CHWs helped to educate the clients about the study objectives, and addressed
participant fears and questions in the local language and familiar setting, achieving high
consent rates among the participants who attended the study clinic. CHWs also reduced
the need for lengthy study descriptions at the clinic as these had previously been
provided, allowing for more time dedicated to medical or counseling needs. Also, all
study personnel in Zambia were local people who helped in establishment of contacts and
gaining the trust of study participants. This was critical in achieving enrollment goals and
high follow-up rates. In our experience, research studies in Zambia will greatly benefit by
clearly defining and explaining the benefits to study participants. High poverty level
makes it difficult to garner interest about research studies in these participants because
their individual problems are so severe that they have little time, energy or resources for
participating in research studies.
Cohort studies are a challenge to plan and execute, even more so in a lowresource setting such as Zambia. In our experience, high-tech equipment does not work
well without constant technical support. We believe that one of the reasons behind
malfunctioning of the scanning software was the lack of firewall protection to the UTH
network of computers. Affordable internet in Zambia is often slow and unreliable making
many tasks tedious. Also, another common problem faced by the study personnel was
ensuring that the enrolled household was indeed one unit. To establish this, all
relationships were asked to be clearly defined by the client. For example, a client
describing her sister’s son as “like a son” was further queried to understand if the client
was taking care of the child briefly or that the child was indeed living with the household.
The household structure in Zambia is markedly different from Western countries with a
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common joint family system, leading to large household size. Addition of new household
members is also common because of relatives staying for extended periods of time, as is
the caring for young children whose one or both parents have died. Careful planning and
explanation of definition of household is essential for such studies.
This study design had several strengths. Most epidemiological studies on HHV-8
reported to-date are cross-sectional in design and cannot provide incidence estimates
during early childhood in relation to the factors that may be associated with increased
incidence. Also, very few studies have focused on studying infection within households
especially in endemic areas like Zambia. Unlike Western countries, where primary
infection mostly occurs after adolescence, our previous studies have shown that children
are infected in Zambia at a young age [10]. We have a unique opportunity to study
whether the source of infection is from within or outside the household. But despite
careful planning, this cohort may still have certain limitations. We were unable to recruit
households from more affluent backgrounds, thus limiting the ability to generalize our
findings to different living situations. However, with 64% of Zambian households living
in poverty, our results will be generalizable to the majority of Zambian population. Also,
since we had to limit the household size to 10, we may have missed the effect of larger
household size on HHV-8 acquisition. Another potential limitation could be self-selection
bias; because of provision of medical benefits, the participants in the study may have
been of poorer overall health due to HHV-8 or HIV infection, and had more of an
incentive to be enrolled as well as to continue follow-up. If a selection bias was present,
we will still be able to assess HHV-8 acquisition, using information about overall health
of individuals as predictor variables. Another limitation could be informational bias;
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some of the questions regarding eating habits or personal care habits may incite a
defensive response in the caregiver, resulting in answers that err towards more socially
acceptable habits. To decrease this potential bias, the questionnaire was carefully worded
to avoid possible negative connotation, and the nurses were instructed to ask questions in
a non-judgmental manner. In addition, since participants were informed of their and their
child’s HHV-8 status at follow-up visits, this could potentially alter their interactions
with the child. The caregiver could assume that certain behaviors that were being asked
on a regular basis were important and may change their behavior. To avoid this,
participants were not instructed that any questioned behaviors were known to be
associated with HHV-8 transmission.
The results from this study have the potential to contribute towards the design of
effective health behavior interventions for prevention of HHV-8 infection and overall
community health promotion. Designing effective behavioral interventions to prevent
HHV-8 transmission to young children requires us to investigate the degree to which that
behavior is influenced by attitudes, perceived norms, and self-efficacy. The questionnaire
data collected from study participants will be critical in understanding these potential
determinants of transmission. The laboratory and virological data will help in
understanding the biology of HHV-8 in the Zambian setting. To summarize, this study
was designed to yield critical clinical, demographic, laboratory and behavioral data useful
for answering a variety of questions about HHV-8 transmission, including: Does a child
acquire HHV-8 infection from within a household? Does HIV-1 infection of the child or
household member increase risk of HHV-8 acquisition in a child? What behavioral or life
style risk factors increase the risk of acquiring HHV-8 by a child?
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TABLES AND FIGURES
FIGURE 1.
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FIGURE 1. Outline Map of Zambia Depicting the Nine Provinces. City of Lusaka, the
capital of Zambia, is a part of Lusaka district (shaded black). Lusaka District is a part of
Lusaka province (shaded gray). Detailed Area Map of District of Lusaka, Zambia
Showing the Distribution of Townships of the Households (N=1600) that were Screened
for Enrollment in the Zambia Children’s KS-HHV8 study, 2004-2009. No. – Number,
UTH – University Teaching Hospital
Note:
Number of households (n) enrolled from each township is indicated. Symbols represent
the percentage of households enrolled from each township; filled squares- ≥10%, filled
circles- 5-9.9%, open squares- 1-4.9%, open circles- <1%.
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FIGURE 2.

FIGURE 2. Flow Chart Describing the Recruitment of the Study Cohort for The Zambia
Children’s KS-HHV8 Study, Lusaka, Zambia, 2004-2009.

TABLE 1. Questionnaires, Biological Specimens Collected and Laboratory Measures for the Zambia Children’s KS-HHV8 Study,
Lusaka, Zambia, 2004-2009.
Visit

Questionnaire
Screening questionnaire for
eligibility
Screening
Enrollment Enrollment questionnaire for:

Blood
Blood, buccal swab

- basic medical examination
- demographic characteristics
- baseline data
- household behavioral data
-developmental milestones
Follow-up questionnaire

HHV-8
HIV, CD4 count,
HHV-8 serology, DNA shedding in buccal
swabs
Others, if indicated (Malaria, Syphillis)

Blood, buccal swab

HIV, CD4 count,
HHV-8 serology, DNA shedding in buccal
swabs
Others, if indicated (Malaria, Syphillis)

Follow-up

- basic medical examination
- changes in medical conditions
- household behavioral data
-developmental milestones

Samples collected

Tests performed
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TABLE 2. Enrollment Characteristics of study Participants During Each Year of the Zambia Children’s KS-HHV8 study, Lusaka,
Zambia, 2004-2009.
Year 2004
Year 2005
Year 2006
Year 2007
Year 2008
Total
Number (%)
Number (%)
Number (%)
Number (%)
Number (%)
Number (%)
Index Children
Sex
Female
Male
Age, months
0-5
6-12
13-18
19-24
25-29
Household Members

n=11

n=171

n=151

n=92

n=39

n=464

6 (54.5)
5 (45.5)

81 (47.4)
90 (52.6)

62 (41.1)
89 (58.9)

46 (50.0)
46 (50.0)

24 (61.5)
15 (38.5)

219 (47.2)
245 (52.8)

0
4
6
1

0
61
42
51

9
64
36
41

15
45
19
10

2
33
4
0

26
207
107
103

0
n=38

17
n=567

1
n=500

3
n=226

0
n=4

21
n=1335

19 (50.0)
19 (50.0)

321 (56.6)
246 (43.4)

288 (57.6)
212 (42.4)

136 (60.2)
90 (39.8)

2 (50.0)
2 (50.0)

766 (57.4)
569 (42.6)

9

104

89

39

0

241

9
20

197
266

171
240

70
117

2
2

449
645

49

738

651

318

43

1799

Sex
Female
Male
Age, years
≤ 5, Child
6-15, Youth
> 15, Adult
Total Enrolled

67

68
TABLE 3. Characteristics of 368 Enrolled Households in the Zambia Children’s KSHHV8 study, Lusaka, Zambia, 2004-2009.
Characteristic
Number of Household members
≤3
4-5
>5
Number of rooms in home
1
2-3
≥4
Electricity in home
Yes
No
Toilet in home
Shared outhouse (latrine)
Flush toilet in own house
Water source
Community tap or shared with neighbors
Tap outside on property or in own house

N (%)
87 (23.6)
175 (47.6)
106 (28.8)
89 (24.2)
223 (60.6)
23 (6.3)
64 (17.4)
270 (73.4)
329 (89.4)
6 (1.6)
291 (79.1)
44 (12.0)

Note: All numbers do not equal total household numbers due to missing values

69
TABLE 4. Characteristics of Primary Caregiver in the Zambia Children’s KS-HHV8
study conducted in Lusaka, Zambia, 2004-2009.
Characteristic
Primary caregiver relationship to index child (N=464)
Mother
Grandmother
Aunt
Father
Cousin
Primary caregiver age (years) (N=368)
<20
20-29
30-39
≥40
Parental caregiver status within households (N=368)
Households with two parents
Households with single parent
Households with extended family
Education of the primary caregiver† (N=368)
None
Primary
Secondary

N (%)
449 (96.8)
6 (1.3)
7 (1.5)
1 (0.2)
1 (0.2)
25 (6.8)
200 (54.3)
120 (32.6)
23 (6.3)
185 (50.3)
130(35.3)
53 (14.4)
33 (9.0)
200 (54.3)
102 (27.7)

Note: All numbers do not equal total household numbers due to missing values
†
A Primary caregiver is defined as the household member with the most contact with the
child.
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ABSTRACT
Background: Human herpesvirus-8 (HHV-8) infection in early childhood is common
throughout sub-Saharan Africa with prevalence increasing throughout childhood.
Specific routes of transmission have not been clearly delineated, though HHV-8 is
present in high concentrations in saliva.
Methods: To understand the horizontal transmission of HHV-8 within households to
children we enrolled for cross-sectional analysis; 251 households including 254 children,
age two and under, in Lusaka, Zambia. For all children, plasma was screened for HHV-8
and HIV-1 and health and behavioral questionnaires were completed. Multi-level logistic
regression analysis was conducted to assess independent factors for HHV-8 infection in
children.
Results: Risk factors for HHV-8 infection included increasing number of HHV-8 positive
household members [OR 2.5 (95% CI: 1.9, 3.3) P < 0.01] and having a primary caregiver
who tested the temperature of food with their tongue prior to feeding the child [OR 2.4
(95% CI: 1.93, 3.30) P =0.01]. Breastfeeding was protective against infection with HHV8 for children [OR 0.3 (95% CI: 0.16, 0.72) P <0.01].
Conclusions: These results demonstrate that exposure to HHV-8 in the household
increases risk for early childhood infection with specific feeding behaviors likely playing
a role in transmission.
Impact: Interventions to protect children from infection should emphasize the possibility
of infection through sharing of foods.
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INTRODUCTION
Human herpesvirus 8 (HHV-8) is the most recently discovered member of the
gamma- herpesvirus family [1]. Also known as Kaposi’s sarcoma-associated herpesvirus
(KSHV), it is known to be the causative agent of Kaposi’s sarcoma (KS), as well as other
malignancies such as primary effusion lymphoma [2] and multicentric Castleman’s
disease [3]. Seroprevalence of HHV-8 depicts uneven distribution worldwide but is
generally high in areas where non-HIV associated forms of KS (classic or endemic
forms) are common [4]. Results of epidemiological studies on HHV-8 seroprevalence in
African adults vary from 29% to 48% based on region and population group [5-7]. In
children, seroprevalence differs significantly with age and between different geographical
regions, and the prevalence of infection increases consistently throughout childhood and
adolescence in young children in some endemic areas of Africa such as Zambia [8].
Prior to the onset of the HIV/AIDS epidemic in the mid 1980’s, KS was rare in
children even in KS endemic areas such as sub-Saharan Africa [9-13]. During the
HIV/AIDS epidemic, KS incidence rates in Africa increased dramatically in both adults
and children [14]. In Zambia, pediatric KS incidence increased from 3.2% to 19.0% as a
direct result of the HIV/AIDS epidemic [10], and by 1990 constituted 20-25% of all
Zambian pediatric malignancies [12]. Given the high prevalence of HIV infection in the
population, this may have been associated with either an increased risk of acquisition of
HHV-8 infection or an increased risk of HHV-8 transmission to young children. Hence,
there is a need for a better understanding of the frequency of HHV-8 transmission during
early childhood.
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In both Western and developing countries, the risk for HHV-8 infection is likely
associated with horizontal transmission through saliva however; in children there is a
paucity of data regarding when and how transmission occurs and, in particular, which
behavioral factors are associated with an increased risk of transmission. Several studies
have shown that horizontal transmission occurs within families, most likely through
saliva exchange [15-17]. Our laboratory has previously reported the isolation of HHV-8
viral DNA in saliva samples from seropositive mothers in Zambia. Results from these
studies strongly suggest that child rearing behaviors associated with saliva exposure
could be a risk factor for increased HHV-8 transmission [18]. Results from a recent study
conducted in rural Uganda lend credence to this theory when it reported a possible, albeit
weak association between variables associated with saliva exposure such as sharing of
food and/or sauce plates and increased risk for infection with HHV-8 [19].
Our earlier longitudinal cohort study demonstrated that children in Zambia
acquire HHV-8 infection early in life, with up to 40% of children being infected by 48
months of age [20]. These results provide compelling evidence that horizontal
transmission of HHV-8 infection during early childhood is associated with the high
incidence of infection in children. Therefore, we hypothesized that behaviors associated
with saliva exchange, such as sharing food, would increase the risk for HHV-8
seropositivity. To date, no large epidemiological study has been conducted in an endemic
area such as Zambia to investigate horizontal transmission of HHV-8 infection from
within a household to children. In the present analysis we evaluated behavioral risk
factors associated with household saliva exposure to delineate risk factors for HHV-8
infection in young children in Zambia.
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MATERIALS AND METHODS
Study design and population
The present study is a part of a larger longitudinal cohort study recruited for the
purpose of determining of risk factors for early childhood infection with HHV8 n
Zambia. This is a collaborative study among investigators at the University of NebraskaLincoln and the University Teaching Hospital (UTH) of University of Zambia School of
Medicine in Lusaka, Zambia to study HHV-8 and HIV infections in Zambia. Details of
the study design, rationale and recruitment process for this study have been previously
described in detail [21]. In brief, participant recruitment was conducted from August of
2004 to April of 2007 at the KS/HHV8 Study Clinic situated within UTH. Community
workers were hired from eligible participants in our previous mother to child HHV-8
cohort transmission study specifically to inform community members about the study and
to help with the screening and enrollment process [21].
Inclusion criteria for enrollment were as follows; families with a child less than 2
years of age (the index child), a resident of Lusaka, all family members willing to
participate in annual follow-up visits and the primary caregiver and index child should
commit to 4-month follow-up visits. The primary caregiver was the family member selfdescribed as the individual with the most individual contact with and providing care for
the index child. Of the enrolled children, 75 HHV-8 positive children chosen at random
were also enrolled for the present analysis to understand the risk factors associated with
HHV-8 prevalence in this cohort. These children were randomly selected if the caregiver
expressed the willingness to participate.
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Written consent was obtained from the study participants after describing the
purpose of the study. Informed consent was obtained from all adult participants, and
primary caregivers provided consent for children in the household. Study approval was
granted by the Institutional Review Boards of the University of Zambia and the
University of Nebraska and all suggestions and modifications were incorporated in the
study protocols.
Data collection and measures
The primary caregiver in each household was interviewed by trained study nurses
using structured questionnaires that included questions on socio-demographic variables
(gender, age, education of the primary caregiver, household size, number of playmates),
household living conditions (electricity, water source, toilet type, number of
rooms/sleeping areas, household density), behaviors involving food and drink
(premastication of food , sharing sweets and/or drinks), and healthcare and personal care
practices (bathing habits, use of traditional medicine, and use of saliva to clean children’s
faces , soothe injuries or insect bites). The questionnaires were written, designed and
initially tested on focus groups in 2004 before study enrollment was initiated [22].
Laboratory testing
Sample collection. Blood samples were collected by venipuncture from all members of
the household within eight months (mean 2.3 months) of each other. Family size is often
large in Zambian households and everyone in the family is often unable to attend the
clinic at the same time. HIV-1 testing was performed at the UTH clinic in Lusaka,
Zambia and PBMC’s were isolated for PCR analysis for HIV-1 positive individuals.
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Plasma samples were shipped to University of Nebraska-Lincoln, Nebraska for HHV-8
serological analysis.
HIV-1 Serology. Plasma was screened for HIV-1 antibodies using both Capillus
(Cambridge Biotech), and Determine (Abbott Laboratories) according to the
manufacturer’s instructions. A result was considered positive if one or both of these rapid
screening assays revealed a positive result. For children under 18 months of age, early
infant diagnosis using dried blood spot (DBS) was conducted. If children under 18
months of age were found to be seropositive but no confirmatory DBS data was
available, serostatus was based on serology results that were obtained at subsequent
follow-up visits (>18 months of age). If follow-up visits were not completed, the HIV-1
result was considered indeterminant.
HHV-8 Serology. HHV-8 serological testing was conducted using a monoclonal
antibody-enhanced immunofluorescence assay (mIFA). Plasma samples were diluted
1:40 in phosphate buffered saline, and screening was performed on BC-3 cells (an
Epstein-Barr virus negative and HHV-8 positive cell line) (American Type Culture
Collection, Manassas, Virginia). BC-3 cells were grown in RPMI media supplemented
with 20% heat-inactivated fetal calf serum, and antibiotics (100 U/ml penicillin, 100
µg/ml streptomycin). Cells were stimulated to promote HHV-8 lytic cycle with 20 ng/ml
of tetradecanoyl phorbal ester acetate. At 48 hours post stimulation, cells were fixed
using 4% paraformaldehyde, permeablized using 0.1% Triton X-100, and then spotted on
12-well teflon coated slides. The mIFA was performed with mouse monoclonal antihuman IgG antibody (CRL 1786) (American Type Culture Collection, Manassas,
Virginia) as secondary antibody, and DyLight 488-conjugated donkey anti-mouse IgG
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(Thermo Scientific) as tertiary antibody. A plasma sample was considered to be positive
if two readers independently determined the sample to be positive on two independent
mIFA tests. Positive samples were tested on BJAB cells (an Epstein-Barr virus negative
and HHV-8 negative B cell line) which performed the role of negative controls to rule out
any non-specific binding of antibodies to cells.
Data analysis
Dataset for the present analysis was built and statistical analysis was conducted
using SAS (v9.2) (Cary, NC, USA). Logistic regression model with manual forward
stepwise selection was conducted to explore the strength and significant association
between HHV-8 seroprevalence (outcome) and a range of household behavioral habits
(covariates). Associations between covariates and outcome were also evaluated to
identify potential confounders. Odds ratios (ORs), 95% confidence intervals (CI) and P
values were calculated to identify risk factors for HHV-8 infection in children under 2
years of age. Variables with a P value <0.05 in univariable analysis were included in a
multivariable logistic regression model utilizing a manual forward selection process, to
control for possible confounders and identify independent associations. Anthropometric Z
scores were calculated using the NUTSTAT anthropometric software package (Epi Info,
version 3.2.2; Centers for Disease Control and Prevention). Three households had
multiple index children in one household. To account for a clustering affect, the data was
also analyzed utilizing GEE logit link type 3 analyses though we did not observe any
influence of clustering on the final results.
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RESULTS
We screened index children under the age of 24 months from 1,600 households
within the city of Lusaka, Zambia. Eligibility criteria were met by participants of 1,023
households. Of these, 622 primary caregivers along with their index children returned for
enrollment and 368 of these returned with the complete household. There were 117
households that had incomplete data and record completion at enrollment, thus
information from 251 households was available for analysis. Total enrollment in the
study included 251 households with 254 index children, and 877 family members as
outlined in Figure 1. Of the 254 index children enrolled, 75 (29.5%) were HHV-8
positive. Table 1 summarizes the characteristics of the HHV8 positive and negative
children, their household sizes, primary caregivers, and the HHV-8 status of the
household members. Comparison of behavioral habits related to the care of the index
child that could be potential risk factors for HHV-8 transmission to children was
conducted in the group of HHV-8 positive children as compared to HHV-8 negative
children. On univariate analysis, we found significant associations between the HHV-8
serostatus of the primary caregiver including mother and father, youth and children in the
household and risk for HHV-8 infection in the index child (Table 2). Specifically, an
increased risk for HHV-8 infection was associated with a child having a primary
caregiver who was HHV-8 positive [OR = 2.5 (95% CI: 1.44, 4.32) P <0.01]. There was
a slightly stronger association if the mother was HHV-8 positive as opposed to other
caregivers [OR = 2.7 (95% CI: 1.48, 4.77) P <0.01]. However, an increased risk for
HHV-8 prevalence was associated with having any HHV-8 positive adult household
member [OR = 2.1 (95% CI: 1.11, 3.92) P = 0.03], and there was an increased odds of
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1.8 [(95% CI: 1.22, 2.51) P <0.01], for every additional adult household member who
was HHV-8 positive. The increasing total number of HHV-8 positive household
members, including youth, was associated with an even higher odds of 2.5 (95% CI: 1.91,
3.21) P <0.01.
We found no associations between child anthropometrics (weight and height
percentiles), and risk for HHV-8 prevalence (Table 3). Additionally, there was no
association between CD4 and CD8 cell count, hematocrit and hemoglobin levels and risk
for HHV-8 prevalence in children (Table 3). The association between HHV-8 prevalence
and socio-demographic variables was also examined, including age, gender, number of
household members categorized by age, relationship of primary caregiver to index child,
parental age, and primary caregiver education. There was an increased risk associated
with having a greater number of adults in the household (Number of household members
> 15 years of age) [OR = 1.5 (95% CI: 0.99, 2.18) P = 0.05] (Table 3), however we found
no association between the other variables including child age, gender, adult age,
education level and increased risk of infection.
We also examined for an association between HHV-8 seroprevalence in children
and household and community specific living condition covariates including crowding,
water source, toilet availability, number of rooms and sleeping areas in the home,
crowding of persons in sleeping areas, number of playmates and number of playmates
under the age of 5, and number of times weekly the index child spends overnight with
friends. No associations were found with any of these covariates and child HHV-8
serostatus (Table 4). Similarly, we found no association between HHV-8 seroprevalence
in children and health and hygiene exposures including number of full-body baths, daily
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face cleanings, use of traditional medicine, and use of saliva to clean child’s face, soothe
childhood injuries, or insect bites (Table 4) although having a toilet within the household
was marginally significant for protecting against HHV-8 infection [OR = 0.1 (95% CI:
0.01, 1.34) P=0.09).
We also investigated covariates related to feeding practices to investigate the
association with HHV-8 seroprevalence and observed that there was decreased odds of
HHV-8 seropositivity when the children was currently being breastfed [OR = 0.5 (95%
CI: 0.27, 0.88) P = 0.01] or if the child had ever been breastfed [OR = 0.4 (95% CI: 0.21,
0.74) P <0.01] (Table 5). A number of feeding practices that involved exchange of saliva
were evaluated to assess for association with HHV-8 prevalence including premastication
and sharing of foods. Having a HHV-8 positive caregiver premasticate the food prior to
feeding the child did not demonstrate significantly increased odds for HHV-8 prevalence,
although a small number of caregivers indicated that this practice was performed limiting
our overall sample size (data not shown).
Upon multivariable logistic regression analysis, an independent association for
HHV-8 prevalence included total number of HHV-8 positive household members [OR =
2.5 (95% CI: 1.93, 3.30) P< 0.01] or having the primary caregiver taste the temperature
of the food prior to feeding [OR = 2.4 (95% CI: 1.19, 4.73) P = 0.01] (Table 6). Current
or past breastfeeding [OR = 0.3 (95% CI: 0.16, 0.72) P <0.01] was protective against
infection with HHV-8.
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DISCUSSION
In sub-Saharan Africa children become infected with HHV-8 at an early age.
Our cohort studies have reported that by 13.4% of Zambian children were infected 12
months of age [23]. An additional Ugandan study found comparable levels of infection
by 2 years of age [24]. Zambia is a part of the “KS belt”, an area with endemic KS that
has been severely impacted subsequently by the HIV epidemic, underscoring the need for
epidemiologic studies to better understand patterns of HHV-8 transmission in young
children. Although sexual transmission in adults and mucosal shedding of HHV-8 along
with salivary exposure has been implicated in the transmission of HHV-8 in adults, there
is little information about routes of transmission in children, and behavioral habits that
could be potential risk factors and sources of transmission within the family.
Although other studies have examined childhood HHV-8 infection as a result of
transmission between mother and child or between siblings [17, 25, 26], few have
examined specific household behaviors that could contribute to virus transmission to a
susceptible child within a household. The strengths of our study include utilization of a
detailed questionnaire designed to assess behavioral habits not only engaged by the
mother, but by household members and even the child’s interaction with neighborhood
children. Ours is one of the first studies demonstrating an association between behavioral
factors associated with saliva exchange, specifically feeding practices such as testing
food prior to feeding, and infection with HHV-8 in early childhood. Butler et al.
previously demonstrated a significant association with HHV-8 in children <14 years of
age and sharing a sauce plate with other household members [19]. Our study did not
demonstrate a significant association in any of our household food sharing variables in

82
the univariable analysis, most importantly, an absence of any association with
premastication, however our sample size was small in contrast with other studies [19].
However, we did observe that in the multivariable analysis a specific behavior i.e. the
primary caregiver testing temperature of food prior to feeding was associated with HHV8 prevalence, which potentially supports Butler et al’s association with food sharing
behaviors [19].
In the present study, we observed that presence and number of HHV-8 positive
household members was consistently associated with childhood HHV-8 infection. This
suggests person-to-person contact with HHV-8 positive members is likely to play a key
role in transmission. These results have been further confirmed by a study completed in
our lab utilizing molecular analysis of the K1 gene sequence data of KSHV-positive
individuals from nine households in our cohort [27]. Olp et al found that in six of the nine
households, the child had 100% sequence identify to all household members, supporting
that intra-household transmission occurs [27].
Our study tested multiple behavioral habits of caregivers and household members
in which saliva exchange could occur with the child. We also investigated whether these
behaviors were practiced by the primary caregiver, or if the primary caregiver observed
other household members practicing the behavior to test the hypothesis that HHV-8 was
spread through child-rearing behaviors associated with saliva exposure. We observed that
both the primary caregiver’s and the mother’s HHV-8 status were the most significant
factors, most likely due to more frequent and close person-to-person contact. This
contact likely occurs during food exchange behaviors, when possible saliva exchange
occurs. But in this study, none of the child rearing behaviors individually were associated
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with HHV-8 prevalence with the exception of the primary caregiver testing the
temperature of the food before feeding the child. It is likely that for a HHV-8
transmission event to occur the amount of saliva and the amount of viral shedding at the
time of the behavior may be key factors. Seroreversion, the fluctuation in antibody titers
to undetectable levels, in adults is well documented, and could correlate to viral shedding
and likelihood of transmission. Also, the frequency of occurrence of each behavior over
time could be critical but this was not fully explored in this study. It is also likely that the
behavioral habits analyzed in this study such as sharing drinks and foods, involve
exposure to only minimal amount of saliva. Similarly, Butler et al’s (2011) paper,
reporting only a marginal association of sharing food and/or sauce plates with HHV-8
infection in children could support the fact that the amount or frequency of saliva sharing
could be a factor [19].
Breastfeeding as a protection against HHV-8 infection is a novel finding among
herpesviruses. Breast milk has been implicated in mother to child transmission of several
viruses, including cytomegalovirus and HIV-1 [28, 29]. However, to our knowledge, this
is the first report of breastfeeding as protection against childhood infection of HHV-8 or
any herpesvirus. It is likely that there may be non-specific immune factors responsible for
breast milk protection, including lactoferrin, complement components, or even
commensal organisms. Overall, our finding of the decreased risk of HHV-8 infection
associated with breastfeeding is intriguing and warrants further studies to identify the
protective factors that may be responsible.
HIV-1 infection has been documented to be a risk factor associated with HHV-8
infection. However, we did not analyze the association of HIV-1 with HHV-8 infection in
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the current study, because our subjects were selected to be HHV-8 negative as part of a
larger longitudinal study with an aim to study HHV-8 incidence in early childhood. Our
earlier cohort studies have clearly demonstrated that HIV infected children are at a
significantly higher risk for acquiring HHV-8 infection [23]. Therefore, during the
enrollment of this cohort, in which HHV-8 negative children were being recruited, it is
likely that HIV-1 positive children were under-represented because they were already
HHV-8 infected.
A limitation of our study is that the behavioral questions were self-reported which
could potentially result in recall bias. HIV-1 status of the household members was
reported to the study subjects at study enrollment and counseling was done regarding
transmission of HIV-1 and preventative health measures. However, since HHV-8 status
was not known by the caregivers at the time of the study, we do not believe that this
potential for bias was a significant factor.
In summary, we have demonstrated that the presence of HHV-8 in the household
plays a key role in transmission of the virus to a susceptible child. This likely occurs
through saliva sharing during behaviors such as testing the temperature before sharing to
the child. This finding has implications for public health risk, and the need for education
of families of potential transmission of the virus when sharing food with young children,
and needed behavior changes. Although the current analysis supports the view that the
primary caregiver poses the most significant risk of transmitting HHV-8 infection to a
child, other results from the same cohort also demonstrate that HHV-8 transmission to a
child can also occur from other household members and even from others outside of the
household [27]. Whether similar factors are also associated with HHV-8 incident
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infection in “at-risk” children is the current focus of this study. Longitudinally followed
children in this cohort up to 48 months after enrollment will improve our understanding
of the nature of interpersonal contact with a child and its role in HHV-8 transmission.
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TABLES AND FIGURES
Table 1. Demographics and HHV-8 Characteristics of HHV-8 Positive and HHV-8
Negative Children in Lusaka, Zambia, 2004-2007.

Characteristic
Demographics
Age of index child (months):
Range
Mean
Sex of index child:
Males
Females
Number of household members:
Range
Mean
Number of adults:
Range
Mean
Age of primary caregiver (years):
Range
Mean
Education of primary caregiver:
None
Primary school
Secondary school
Household HHV-8
Primary caregiver HHV-8+
Mother HHV-8+
Father HHV-8+
≥ 1 other household member HHV-8+

HHV8 +
(n=179)

HHV8 (n=75)

4-25
13.4

2-28
13.5

28
47

93
86

2-8
4.7

2-8
4.5

1-4
1.8

1-4
1.7

17-49
28.9

14-58
27.3

7
47
21

18
105
56

52/75 (69.3%)
51/72 (70.8%)
23/36 (63.9%)
68/75 (90.7%)

82/179 (45.8%)
79/175 (45.1%)
44/74 (59.5%)
143/179 (79.9%)

Table 2. Univariable Analysis to Investigate the Association of HHV-8 Serological Status of Household Members with Child HHV-8
Seropositivity in Lusaka, Zambia, 2004-2007.
Characteristic
Adult and Household HHV-8 Risk Factors
≥ 1 household member HHV-8+
Increasing number of HHV-8+ household members
Primary caregiver HHV-8+
Mother HHV-8+
Father HHV-8+
≥ 1 adult household member HHV-8+
Increasing number HHV-8+ adult household members
Youth HHV-8 Risk Factors
≥ 1 household youth HHV-8+
Increasing number of household youth HHV-8+
Any other household child HHV8 +
a

Odds
Ratio

95% Confidence
interval

P value

2.7
2.5
2.5
2.7
1.2
2.1
1.8

1.23, 5.78
1.91, 3.21
1.44, 4.32
1.48, 4.77
0.49, 2.67
1.11, 3.92
1.22, 2.51

0.01a
<0.01a
<0.01a
<0.01a
0.66
0.03a
<0.01a

1.4
1.3
1.3

0.70, 2.84
0.90, 1.99
0.66, 2.74

0.30
0.16
0.52

Significant at α level of 0.05 bTotal numbers vary reflecting family members enrolled in study
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Table 3. Univariable Analysis to Investigate the Association of Socio-Demographic
Factors and Nutritional and Immunological Factors with Child HHV-8 Seropositivity in
Lusaka, Zambia, 2004-2007.

Characteristic
Child specific characteristics
Age of index child (months)
Gender of index child (Reference: male)
Household specific characteristics
Number of household members
Number of household adults > 15 yrs
Number of household youth (age > 5, ≤ 15yrs)
Number of household children (age ≤ 5 yrs)
Two parents vs. single parent household
Extended family parenting vs. single parent
household
Caregiver and adult specific characteristics
Relationship of primary caregiver to index child:
- Aunt vs. Mother
- Grandmother vs. Mother
Maternal age (years)
Paternal age (years)
Primary caregiver age (years)
Primary caregiver education:
- No school vs. junior primary
- No school vs. upper primary
- No school vs. junior secondary
- No school vs. upper secondary
Nutritional status indicators
Length-for-age or stature-for-age percentile
Weight-for-length or weight-for-stature percentile
Weight-for-age percentile
Laboratory values
CD4 count
CD8 count
Hematocrit
Hematocrit (normal)
Hemoglobin
a

Significant at α level of 0.05

Odds
Ratio

95%
Confidence
interval

P value

1.0
0.6

0.96, 1.04
0.37, 1.19

0.99
0.12

1.1
1.5
1.1
1.0
1.6

0.94, 1.36
0.99, 2.18
0.85, 1.37
0.68, 1.52
0.86, 2.93

0.18
0.05a
0.51
0.93
0.45

1.6

0.75, 3.58

0.45

5.0
0.7
1.0
1.0
1.0

0.44, 56.0
0.27, 10.2
0.99, 1.08
0.98, 1.06
0.99, 1.08

0.99
0.98
0.13
0.42
0.10

1.5
1.1
1.1
0.7

0.48, 4.53
0.41, 2.79
0.38, 3.19
0.21, 2.59

0.30
0.93
0.87
0.37

1.0
1.0
1.0

0.99, 1.01
0.99, 1.00
0.99, 1.00

0.70
0.42
0.13

1.0
1.0
1.1
1.2
1.3

0.99, 1.00
0.99, 1.00
0.86, 1.48
0.44, 3.11
0.76, 2.30

0.27
0.18
0.39
0.76
0.33

Table 4. Univariable Analysis to Investigate the Association of Household and Personal Care Factors with Child HHV-8
Seropositivity in Lusaka, Zambia, 2004-2007.
Characteristic
Household and Community Characteristics
Water source (Community vs. within household)
Toilet location (Community vs. within household)
Number of rooms in the household
Number of sleeping areas in the household
Persons per sleeping area
Number of playmates
Number of playmates < age 5
Hygiene practices
Number of daily full-body baths for index child
Number of daily face cleanings for index child
Saliva used to clean child's face
Biting the child's nails to shorten them
Health practices
Saliva used to soothe insect bites
Caregiver sucks mucus from child’s nose
Traditional teething remedies used
Use of Traditional Medicine
Lifebuoy soap for constipation

Odds Ratio 95% Confidence interval P value
0.9
0.1
1.2
1.4
1.0
1.0
1.0

0.41, 2.12
0.01, 1.34
1.00, 1.54
0.94, 2.19
0.79, 1.32
0.91, 1.23
0.84, 1.29

0.85
0.09
0.12
0.10
0.90
0.99
0.61

1.2
1.1
1.1
0.6

0.59, 2.39
0.51, 2.12
0.42, 2.89
0.34, 1.30

0.58
0.87
0.81
0.21

1.3
1.7
1.0
0.2
1.0

0.41, 4.22
0.56, 4.83
0.72, 1.48
0.03, 1.60
0.54, 2.26

0.60
0.28
0.88
0.13
0.92
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Table 5. Univariable Analysis to Investigate the Association of Child Feeding Behavioral Habits of Household with Child HHV-8
Seropositivity in Lusaka, Zambia, 2004-2007.
95%
Confidence P value
interval

Characteristic

Odds Ratio

Child has ever been breastfed
Child is currently being breastfed
Primary caregiver moistens nipples with saliva prior to breastfeeding
Premastication
Adult premasticates food prior to sharing with children
Primary caregiver performs premastication
Other household members perform the premastication
Adult feeding variables
Primary caregiver testing temp of food with tongue prior to sharing w/
child
Blowing on food prior to sharing with child
Sucking on sweets prior to sharing with child
Child and household food sharing variables
Child shares sweets with other neighborhood children
Child shares sweets with other household members
Child shares drinks with other children
Household members share common utensils for meals
Household members share drinks with child

0.4
0.5
1.0

0.21, 0.74
0.27, 0.88
0.38, 2.21

<0.01a
0.01a
0.96

1.2
1.1
1.8

0.60, 2.72
0.54, 2.47
0.51, 5.68

0.61
0.86
0.35

1.6

0.91, 2.89

0.09

1.1
1.1

0.67, 1.90
0.61, 1.89

0.69
0.80

0.9
1.1
0.5
0.8
1.0

0.44, 2.02
0.64, 1.89
0.24, 1.37
0.34, 1.88
0.50, 1.84

0.71
0.87
0.19
0.58
0.89

Breastfeeding practices

a

Significant at α level of 0.05
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Table 6. Multivariable Analysis to Investigate Independently Associated Risk Factors Associated with HHV-8 Seropositivity in
Children in Lusaka, Zambia, 2004-2007.

Characteristic

Odds Ratio 95% Confidence interval P value

Age of index child (in months)

1.0

0.94, 1.10

0.75

Total number of HHV-8+ household members

2.5

1.93, 3.30

<0.01a

Primary caregiver testing temperature of food prior to feeding

2.4

1.19, 4.73

0.01a

Child breastfed currently or in the past

0.3

0.16, 0.72

<0.01a

a

Significant at α level of 0.05
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FIGURE LEGEND
Figure 1. Flow Chart outlining the screening and recruitment of study cohort in Lusaka,
Zambia, 2004-2007.
Figure 1.

Attended study clinic
N = 1600

Completed interview
N = 1592

Did not provide
consent
n=8
Ineligible
n = 626

Eligible for enrollment
N = 1023
Did not return for
enrollment
n = 401

Enrolled
N = 622

Complete households enrolled
N = 368

Incomplete
households
n =254
Incomplete records
n =117

Households for analysis
N = 251
Index Children
n = 254

Household
members
n =877
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CHAPTER 4: CHILDHOOD FEEDING PRACTICES AS A RISK
FOR CHILDHOOD HHV-8 ACQUISITION
ABSTRACT
Background: Human herpesvirus-8 (HHV-8) infection occurs at an early age in endemic
areas such as sub-Saharan Africa. Although saliva is commonly implicated as the culprit
in viral transmission to young children, specific behavioral practices as sources of
transmission have not been clearly delineated.
Methods: To further investigate specific characteristics and household behaviors that are
associated with the risk of transmission of HHV-8 within households to children in
Lusaka, Zambia, we enrolled and followed 270 children, age two and under. For all
children, plasma was screened for HHV-8 and HIV-1 and health and behavioral
questionnaires were completed. Multi-level Cox proportional hazard analysis was
conducted to assess independent factors for HHV-8 infection in children.
Results: Most significant independent risk factors for HHV-8 seroconversion included
age at seroconversion (P < 0.0001), age at enrollment [HR 2.62 (95% CI: 1.64, 4.21) P <
0.001], child currently being breastfed [HR = 2.13 (95% CI:1.31, 3.44) P = 0.002], use
of pacifier [HR = 9.00 (95% CI:1.65, 49.19) P = 0.01], child HIV-1 status [HR = 2.26
(95% CI:1.19, 4.30) P = 0.013], and other individuals blowing on food prior to sharing
with child [HR = 2.79 (95% CI:1.01, 7.76) P = 0.05].
Conclusions: These results demonstrate behaviors in the household that potentially
expose the young child to HHV-8 through exposure to saliva increases risk for early
childhood infection.
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INTRODUCTION
Human Herpesvirus-8 (HHV-8) or Kaposi’s sarcoma associated herpesvirus
(KSHV) is the eighth known human herpesvirus to be discovered. HHV-8 is known to be
associated with the development of Kaposi’s sarcoma (KS), primary effusion lymphoma,
and multicentric Castleman disease. Seroprevalence of HHV-8 varies according to
geographic location. In the United States and Western Europe, HHV-8 infection is
uncommon in the general population, with higher prevalence in men who have sex with
men (MSM) [1, 2]. In sub-Saharan Africa and Mediterranean regions, HHV-8 is
considered to be endemic, however much is yet to be elucidated regarding HHV-8 risk
factors and transmission. Our lab has previously shown that Zambian children acquired
HHV-8 infection early in life, with up to 40% of children becoming HHV8 positive by 48
months of age [3]. Transmission via breastmilk is a possibility, as cytomegalovirus,
another herpesvirus is transmissible via breastmilk, however HHV-8 DNA is not readily
isolated from breast milk [4-6]. In HHV-8 seropositive mothers high viral titers of HHV8 is frequently isolated in saliva [5-7]. In a previous study from a South African
population, children of mothers with high viral load (>50,000 copies/mL) in saliva, were
nearly three times more likely to be HHV-8 positive, than if the mother did not shed
HHV-8 in saliva [5]. Several studies have shown that transmission of HHV-8 occurs
within households, most likely via saliva exchange [8-10]. Taken together, these findings
implicate salivary transmission as the likely culprit for early childhood infection,
however, the mode by which saliva exchange could occur is unclear. A rural Ugandan
study found food and/or sauce plate sharing within households as an associated risk for
HHV-8 in children under age 14 [11]. These studies support our hypothesis that
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behaviors within the household that expose children to saliva at an early age increase the
risk of childhood acquisition of HHV-8. To investigate horizontal transmission of HHV8 infection from within a household to children, we conducted an epidemiologic study in
collaboration among investigators at the University of Nebraska-Lincoln and the
University Teaching Hospital (UTH) of University of Zambia School of Medicine in
Lusaka, Zambia. In this present study, we report findings from a longitudinal cohort in
order to assess childhood incidence rates of HHV-8 infection and the associated sociodemographic, child feeding and rearing behaviors and health care practices that could be
associated with acquisition of HHV-8 infection.
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METHODS
Study setting
Details of the study design, rationale, and recruitment process for this study have been
described in detail previously [12]. In brief, participants were recruited from August,
2004, to April, 2007 at the study clinic in Lusaka, Zambia. Community workers were
hired to participate in informing community members about the study, recruitment of
eligible study participants, and assist in maintaining follow-up with study participants
[12].
Inclusion criteria for enrollment were; family with a child less than 2 years of age
(the index child), family should be a resident of Lusaka, all family members should be
willing to participate in annual follow-up visits and the primary caregiver and index child
should commit to 4-month follow-up visits. The primary caregiver was the family
member self-described as the individual with the most individual contact with and
provided care for the index child. Children and members of their households who meet
study eligibility criteria, signed informed consent before enrolling into the study. Written
informed consent was obtained from all adult participants, and primary caregivers
provided consent for children in the household.
Once study participants were enrolled, the primary caregiver and index children
returned for follow-up visits every four to six months to reassess their serological status
for HHV-8 and/or HIV, and to complete a risk assessment questionnaire for acquisition
of HHV-8 infection. At each visit, a thorough physical examination was performed, new
blood specimens and saliva specimen collected and tested for HHV-8 and HIV-1
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infection. All family members were assessed at enrollment, with specimen collection and
annually thereafter.
As part of the study incentives, each participant was provided multivitamins and
other medications when indicated and a chance for their infant to be followed-up by a
reputable pediatrician. At all visits, all subjects were provided with counseling about risk
reduction for HIV. Study approval was granted by the Institutional Review Boards of the
University of Zambia and the University of Nebraska.
Data collection and measures
Questionnaires were designed as described in detail in chapter 2. In brief, questionnaires
specific for risk assessment were completed by primary caregivers and evaluated upon
seroconversion of the child. These questionnaires address potential sources of blood or
body fluids from household members to the index child, with detailed questions
surrounding incidents that could possibly account for salivary exposure. Data collected
included: socio-demographics (age, gender, occupation, place of residence, marital status,
number-gender-age of children, number-gender-age of siblings); medical conditions
(height, weight, blood pressure, immunization history, breastfeeding history including
duration, frequency and type of any illness-related signs and symptoms, major disease
history, current medication use); laboratory testing (HIV, HHV-8); household living
conditions (number of people living in the house, number and type of rooms in the house,
nature of the water supply, access to toilet, etc.); family structure (two, one or no parents,
number and type of child’s caretakers: mother, extended family, siblings); household
life-style risk factors (sharing dental cleaning materials, sharing pacifiers, eating with
fingers from a common bowl, sharing drinks); and child care giving behaviors (frequency
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and type of feeding, bathing, face washing, etc.). The questionnaires were written and
designed and initially tested on focus groups in 2004 before study enrollment was
initiated [13].
Laboratory testing
Sample collection. Blood samples were collected by venipuncture from all members of
the household. Family size is often large in Zambian households and everyone in the
family is often unable to attend the clinic at the same time. HIV-1 testing was performed
at the UTH clinic in Lusaka, Zambia and PBMC’s were isolated for PCR analysis for
HIV-1 positive individuals. Plasma samples were shipped to University of NebraskaLincoln, Nebraska for HHV-8 serological analysis.
HHV-8 Serology: Antibodies against HHV-8 latency-associated nuclear antigen (LANA)
and HHV-8 lytic antigens was determined by immunofluorescence assays (IFAs), at a
dilution of 1:40, using a primary effusion lymphoma (BC-3) cell line, negative for
Epstein-Barr virus. The viral lytic cycle was induced by incubating BC-3 cells with 20
ng/mL 12-Otetradecanoylphorbol-13-acetate (TPA) (Sigma) for 48 hours. Fixing of cells
was completed with 4% paraformaldehyde and permeabilized using 0.1% Triton X-100.
Post-fixing, the cells were spotted on 12-well Teflon coated slides and allowed to air dry.
The mIFA signal was enhanced using a monoclonal mouse anti-human IgG antibody
(CRL 1786, ATCC) [14] as the secondary antibody, and DyLightTM 488-conjugated
donkey anti-mouse antibody (Jackson Immuno Research) as the tertiary and detection
antibody. A plasma sample was considered to be positive if two readers independently
determined the sample to be positive on two independent mIFA tests. Positive samples
were tested on BJAB cells (an Epstein-Barr virus negative and HHV-8 negative B cell
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line) which performed the role of negative controls to rule out any non-specific binding
of antibodies to cells.
HIV-1 Serology. Plasma was screened for HIV-1 antibodies using two rapid detection
kits; Capillus (Cambridge Biotech), and Determine (Abbott Laboratories) according to
the manufacturer’s instructions. A result was considered positive if one or both of these
rapid screening assays revealed a positive result. All children born to HIV positive
mothers were also screened for HIV infection. For children under 18 months of age, early
infant diagnosis using dried blood spot (DBS) was conducted. If children under 18
months of age were found to be seropositive but no confirmatory DBS data was
available, serostatus was based on serology results that were obtained at subsequent
follow-up visits (>18 months of age). If follow-up visits were not completed, the HIV-1
result was considered indeterminant.
Data analysis
Dataset was built and statistical analysis was conducted using SAS (v9.2) (Cary, NC,
USA). The crude incidence rate per 100 child-years was calculated by dividing the
number of new HHV-8 seroconverters by the total number of child-years at risk and
multiplying by 100. Seroconverting children contributed HHV-8 free child-years at risk
until testing positive for HHV-8. All data was right censored at 48 months. Cox
proportional hazards modeling was conducted to explore the strength and significant
association between HHV-8 infection (outcome) and each individual characteristic
(covariates). Associations between covariates and outcome were also evaluated to
identify potential confounders. Hazard ratios (HRs), 95% confidence intervals (CI) and P
values were calculated to identify risk factors for HHV-8 infection. All comparisons were
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considered statistically significant at P ≤ 0.05.Variables with a P value ≤ 0.05 in
univariable analysis were included in a multivariable model utilizing a manual forward
stepwise selection process, to control for possible confounders and identify independent
associations.
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RESULTS
Index children and members of 1,600 households were screened for study
eligibility criteria as described elsewhere [12]. As outlined in Figure 1, a total of 270
index children were enrolled in the current study. Of the 1023 initial households eligible
for enrollment, 622 returned for enrollment. There were 254 families unable to return
with all members of their household, these were considered incomplete and were dropped
from the study. The total enrolled were 464 children, comprising 368 households. Of
these children, 75 were tested to be HHV-8 positive at the time of enrollment. Data was
collected separately from these children, and a cross-sectional analysis was performed as
described in chapter 3. Insufficient risk assessments were completed for 119 children,
excluding them from the study. Of the remaining 270 children followed, 137 (50.7%)
children seroconverted to be HHV-8 positive within the four year follow-up time of the
study, and 133 (49.3%) remained negative.
Table 1 summarizes the demographics and characteristics of the HHV-8
seroconverting children, and non-seroconverting children. Of the seroconverting
children, at enrollment 11/137 (8.0%) were HIV-1 positive, and 12/133 (9.0%) were
HIV-1 positive.
The incidence rate of HHV-8 seroconversion in the total cohort of 270 children
was 29.94 per 100 child-years, based on a total of 457.57 child-years of follow-up (see
Table 2). We examined crude incidence rates by primary caregiver and child HIV-1
status, finding for HIV-1 positive children, incidence rates of 29.19 per 100 child-years,
and for HIV-1 negative children, incidence rates of 30.01 per 100 child-years. If the
caregiver was HIV-1 positive, incidence rates were slightly lower, at 25.28 per 100 child-
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years, as compared to if the caregiver was HIV-1 negative, at 34.32 per 100 child-years.
When only HIV-1 negative children were examined, a similar finding was also noted,
with incidence rates for HIV-1 positive caregivers at 24.48 per 100 child-years, and for
HIV-1 negative caregivers at 34.32 per 100 child-years.
Figure 2 presents the probability curves as obtained from Kaplan-Meier survival
analysis. Panel A represents the total cohort, showing the probability of annual HHV-8
infection occurring over the 4 year time span. This rate of seroconversion is also reflected
in Table 3, note the age of seroconversion was highly significant when comparing age
groups of >24M to ≤36M to the reference age of <24M [HR = 0.23 (95% CI: 0.14, 0.37)
P < 0.001] and >36M to the reference age of <24M [HR = 0.02 (95% CI: 0.007, 0.03) P
< 0.001]. These findings demonstrate a higher risk associated with an age of <24M with
HHV-8 seroconversion, and decreasing with age. Figure 2, panel B shows that the
probability of males being HHV-8 free is nearing significance (Log Rank P = 0.08).
Comparison of HIV status of the child, primary caregiver, or any household
member was conducted in the group of HHV-8 seroconverting children to nonseroconverting children. HIV-1 positive status of the mother is nearing significance [HR
= 0.74 (95% CI: 0.53, 1.05) P = 0.09] (Table 3). The probability curve as seen in Figure
2 panel C displays the slightly less probability of a child of an HIV-1 positive caregiver
to become HHV-8 positive (Log Rank P-value = 0.09). HIV-1 status of any other
household member was not significant (Table 3). An HHV-8 positive caregiver showed a
nearly significant risk [HR = 1.38 (95% CI: 0.98, 1.94) P = 0.06], but most notably
significant was the increased risk of the child to seroconvert to HHV-8 for every
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additional household member that is HHV-8 positive [HR = 1.20 (95% CI: 1.06, 1.39) P
= 0.005] (Table 3).
No significant associations were found when examining the associations of
household and living conditions with child HH V-8 seroconversion. This included
variables such as, electricity to the house, water source of the house (well water, vs.
community tap, vs. private water source), number of rooms and sleeping areas in the
household, number of persons in the household, and number of persons per sleeping area
(data not shown).
We found a significant association of the child currently being breastfed with
child HHV-8 seroconversion [HR = 6.26 (95% CI: 4.02, 9.75) P < 0.0001] (Table 4).
Also significant was caregiver premasticating food prior to sharing with children [HR =
3.15 (95% CI: 1.00, 9.98) P = 0.05]. Of interest, all of the adult feeding variables
assessed, including testing food with tongue to assess the temperature prior to feeding to
the child, blowing on the food to cool the temperature of the food prior to feeding to the
child, eating of food with hands from a common bowl at mealtimes, and sharing of eating
utensils with the child were all significant (Table 4). Most significant findings included
other household members testing temperature of food with tongue prior to sharing with
child [HR = 5.52 (95% CI: 2.00, 15.20) P = 0.0009], primary caregiver blowing on food
prior to sharing with child [HR = 4.13 (95% CI: 2.37, 7.19) P < 0.0001], and primary
caregiver sharing of eating utensils with child [HR = 4.28 (95% CI: 2.07, 8.85) P <
0.0001] (Table 4).
Table 5 shows several behavioral habits related to sharing sweets and packaged
drinks that could be potential risk factors for sharing of saliva. All of the behaviors were
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highly significant, demonstrating a risk for the child to seroconvert to HHV-8. The
exception of the primary caregiver sucking on sweets prior to sharing with the child nears
significance [HR = 2.06 (95% CI: 0.90, 4.74) P = 0.09] (Table 4). The sharing of food,
candy, or other sweets was most significant when done with other household children
[HR = 2.97 (95% CI: 1.57, 5.61) P = 0.0008] (Table 4). Sharing of packaged drinks such
as bottled soda was most significant when done with household members other than the
primary caregiver [HR = 4.87 (95% CI: 2.32, 10.21) P < 0.0001] (Table 4). Interestingly,
an association was found with childhood use of a pacifier [HR = 17.62 (95% CI: 4.18,
74.35) P < 0.0001] (Table 4).
We observed significant associations with twice per day full-body baths and face
cleanings for the index child [HR = 4.35 (95% CI: 2.88, 6.57) P ≤ 0.0001] , [HR = 3.95
(95% CI: 2.47, 6.31) P = 0.0001] respectively, but no significance was found if bathing
was performed more than twice daily (Table 6). No significance was found in health
practice behaviors such as sucking mucus from child’s nose, using saliva to clean child’s
face, use of Ashton Powder to relieve teething pain, tooth brushing, biting of nails to
shorten them, or use of Lifebuoy soap for constipation (Table 6).
Significantly higher hazard was found upon investigating the association of
childhood interaction variables and child HHV-8 seroconversion, including number of
playmates (P < 0.0001), and if the number of playmates were under the age of 5 (P <
0.0001). Index child spending the night at someone else’s house within the last 6 months,
and the index child has visiting children spending the night at their house in the last six
months [HR = 4.35 (95% CI: 2.88, 6.57) P ≤ 0.0001] , [HR = 3.95 (95% CI: 2.47, 6.31) P
= 0.0001] respectively (Table 7) had significantly higher hazard of seroconversion.
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However, none of these variables continued to be significant in the multivariable
analysis.
In multivariable analysis, independent associations for childhood HHV-8
acquisition included child age at seroconversion (P < 0.0001), child age at enrollment
[HR = 2.62 (95% CI:1.64, 4.21) P < 0.0001], child currently being breastfed [HR = 2.13
(95% CI:1.31, 3.44) P = 0.002], use of pacifier [HR = 9.00 (95% CI:1.65, 49.19) P =
0.01], number of daily full-body baths for index child ( P = 0.0006], primary caregiver
using saliva to clean child’s face, [HR = 38.69 (95% CI:4.50, 332.75) P = 0.0009] , and
other individuals blowing on food prior to sharing with child [HR = 2.79 (95% CI:1.01,
7.76) P = 0.05]. Interestingly, although child HIV-1 positive status was not found to be
significant in the univariable analysis, it became significant when building the
multivariable model [HR = 2.26 (95% CI:1.19, 4.30) P = 0.013].
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DISCUSSION
Childhood acquisition of HHV-8 in sub-Saharan Africa occurs at an early age.
We had previously reported in an earlier study of Zambian mother and infant pairs,
incidence rates of 13.8 per 100 child-years in children by 48 months of age [3]. Our
current findings of 29.94 per 100 child-years are more than twice as high as our earlier
study findings. This may be explained by the change in HHV-8 serodiagnostic assay
used. For this study we performed IFAs with BC-3 cells, a cell line naturally infected
with HHV-8. Our earlier study utilized a second confirmatory antibody detection assay
developed from Sf9 insect cells, expressing 3 key immunogenic recombinant proteins
[15]. The increased repertoire of antigenic proteins expressed by naturally infected cell
lines increases the sensitivity of the assay, reportedly between 97% to 100% [16]
explaining the differences between our findings. The increased sensitivity can result in a
loss of specificity, however the overall seroprevalence of our current cohort by the end of
the study is 50.7%, which is comparable to 20-60% HHV-8 seroprevalence rates in
young children as reported by other African population studies [10, 17, 18].
Key significant findings in this study include age at seroconversion, significant in
the univariable analysis (P < 0.00001), and the most significant variable in the
multivariable analysis (P < 0.00001). A decreased risk as the child becomes older was
noted when comparing >24M to ≤36M and <24M [HR = 0.016 (95% CI: 0.09, 0.28) P <
0.001], and an even lower risk when comparing >36M [HR = 0.006 (95% CI: 0.002,
0.016) P < 0.001] (Table 8). These findings along with our total cohort incidence rates
support that child seroconversion happens very early in age, often before 24 months of
age.

110
Findings of current breastfeeding as a risk for HHV-8 seroconversion were
unexpected, given previous study findings of a lack of HHV-8 DNA in breastmilk [6].
However, the well documented transmission of herpesvirus family member
cytomegalovirus in breastmilk, and the reports of other labs isolation of HHV-8 DNA in
breastmilk makes transmission a possibility [5]. These findings are in contrast to our
findings reported in chapter 3, in which breastfeeding offered a protection against
childhood HHV-8 infection at cohort enrollment. Several factors could affect these
results, such as duration of breastfeeding, whether saliva was used moisten the nipples,
and age of starting solid foods that this study did not thoroughly investigate. These
conflicting results warrant further studies, including further behavioral assessments and
possibly the investigation of neutralizing antibodies in breastmilk.
Childhood use of a pacifier was significant in univariable analysis, and remained
significant in the multivariable analysis. It is unlikely that the use of the pacifier itself
provides a risk for childhood HHV-8 acquisition, rather the care and cleaning of the
pacifier, and the sharing of the pacifier between children. This is supported by the strong
significance of sharing of food, candy, sweets and drinks behaviors with child HHV-8
seroconversion (Table 5). Interestingly, although behaviors performed by the by the
primary caregiver were significant contributors to risk of childhood HHV-8
seroconversion, several variables associated with risk were performed by other household
members, including other household children. Although interactions with other young
children did not remain significant in the multivariable analysis, the importance of other
HHV-8 positive household members’ contribution to HHV-8 transmission may be
influenced by frequency of sharing, and possibly with other young children due to the
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nature of close personal interactions among children. The significance of transmission
among household members has been confirmed by a study completed in our lab utilizing
molecular analysis of the K1 gene sequence data of HHV-8 positive individuals from
nine households in our cohort [19]. Olp et al found that in six of the nine households, the
child had 100% sequence identify to all household members, supporting that intrahousehold transmission occurs [19].
The most significant adult feeding behavior remaining in the multivariable model
was other household members blowing on food prior to sharing with the child. It is likely
that this variable is not the only behavior contributing to the risk of childhood HHV-8
seroconversion, however confounding among feeding variables and sharing of food,
eliminated many of the significant variables from the univariable analysis in the
multivariable model. A wide confidence interval was noted when analyzing using saliva
to clean child’s face, which likely reflects the very small numbers of primary caregivers
that responded to participating in this behavior.
In the multivariable model as well is the number of daily full-body baths for the
index child. These results suggest that the risk is greater than 2x more for a child that has
baths more than twice daily [HR = 2.18 (95% CI: 1.40, 3.38) P = 0.005]. This result
could reflect bathing water quality, or shared water. Since a majority of these households
do not have water sources on their property, water must be hauled into their households
on a regular basis from a community water source. Bathing water is likely shared among
family members, with the possibility of saliva from family members contaminating the
water. However, there is no noted significance when the full body bathing occurs twice
or more times daily [HR = 0.94 (95% CI: 0.54, 1.62) P = 0.8102]. These findings lend
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doubt to the overall significance of the practice of full-body bathing, most likely making
the significance a spurious finding.
The strengths of this study were the size of the cohort and the prospective nature
of the study. To our knowledge, this is the first prospective study to examine children
during such early childhood years for the acquisition of HHV-8. A similar study by
Butler et al. demonstrated a significant association with HHV-8 children <14 years of age
and the sharing of a sauce plate with other household members [11]. Our detailed
questionnaire enabled us to evaluate whether potential exposures were coming from the
primary caregivers, other family members within the household, or outside of the
household, as well as to assess other food sharing variables such as sweets and drinks.
Butler et al. did not find significance in premastication of food to children and HHV-8
[11]. However their cohort evaluated children of an older age, up to age 14. Although in
our study premastication did not remain significant in multivariable analysis, we did find
a 3x greater risk for a child to seroconvert to be HHV-8 positive if the caregiver
premasticates food prior to sharing with the child when performing the univariable
analysis. Our unique findings could be due to our investigation of young children.
Premastication is an uncommon practice in which caregivers chew up food to a
consistency soft enough for a child just starting to eat solid foods can swallow likely
practiced between the ages of 6-12 months. Although premastication was not found to be
frequently performed in our cohort, the amount of saliva that would be needed to soften
food could pose a risk to the very young child.
The weakness of the study was the self-reported nature of the data from the
behavioral questions. We believe that the potential for recall bias was limited because
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the caregivers were not made aware of their HHV-8 status at the time of enrollment and
counseling and treatment was done regarding transmission of HIV-1 to all study
participants.
In summary, we have demonstrated that behaviors performed in the household
that could potentially share saliva play a key role in transmission of HHV-8 virus to a
susceptible child. Of particular interest are feeding behaviors practiced by adults while
feeding the index child, such as testing the temperature of food with the tongue prior to
feeding to a child. This finding supports a public health risk and the need for education
of families in endemic areas such as Zambia risks involved with sharing food with young
children, and needed behavior changes.
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TABLES AND FIGURES
Table 1. Demographics, HIV-1 and HHV-8 Characteristics of HHV-8 Seroconverters
and Non-seroconverting Children in Lusaka, Zambia, 2004-2009.
HHV-8
seroconverter
(n=137)

Nonseroconverter
(n=133)

Range

2-25

2-29

Mean

12.4

14.2

Males

65

76

Females

72

57

Range

2-8

2-10

Mean

5.4

4.9

None

15

11

Primary school

73

78

Secondary school

49

44

HIV-1 serology at enrollment
Index child HIV-1+

11/137 (8.0%)

12/133 (9.0%)

Primary caregiver HIV-1+

56/137 (40.9%)

65/133 (48.9%)

≥ 1 other household member HIV-1+

69/137 (50.4%)

71/133 (53.4%)

66/135a (48.9%)

47/129a (36.4%)

94/137 (70.8%)

83/133 (62.4%)

0-7

0-4

Characteristic
Demographics
Enrollment age of index child (months):

Sex of index child:

Number of household members:

Education of primary caregiver:

HHV-8 serology at enrollment
Primary caregiver HHV-8+
≥ 1 other household member HHV-8+ (other
than primary caregiver)
Number of HHV-8+ household members:
Range
a

Mean
1.8
1.4
Numbers do not match total due to discrepant or unavailable serology at enrollment

Table 2. Seroincidence rates Child HHV-8 Seroconversion in Lusaka, Zambia, 2004-2009.
Number of
Children

Number
Seroconverted

KSHV free childyears

Incidence
(per 100 child-years)

270

137

457.57

29.94

Male

141

65

255.50

25.44

Female

129

72

202.06

35.63

Positive

23

11

37.69

29.19

Negative

247

126

419.88

30.01

Positive

121

56

221.54

25.28

Negative

149

81

236.03

34.32

Caregiver HIV Status
(HIV negative child)
Positive

98

45

183.85

24.48

Negative

149

81

236.03

34.32

Characteristic
Total
Gender

Child HIV Status

Caregiver HIV Status
(total cohort)
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Table 3. Univariable Analysis to Investigate the Association of Gender, Age, Caregiver and Household Characteristics with Child
HHV-8 Seroconversion in Lusaka, Zambia, 2004-2009.
Characteristic
Hazard Ratio (95% CI)
P-value
Child specific characteristics
Gender of Index Child (Reference: Females)
Age at enrollment (Ref: <12M)
Age at Seroconversion:
<24M
>24M to ≤36M
>36M
Caregiver and household member specific characteristics
Primary caregiver education:
No education
Junior Primary
Upper Primary
Junior Secondary
Upper Secondary
Caregiver HIV status(enrollment) (Ref: Negative)
Child HIV status (Ref: Negative)
Any household member HIV status (Ref: Negative)

0.09

0.65 (0.46 - 0.92)

0.01*
<0.0001*

Reference
0.23 (0.14 - 0.37)
0.02 (0.007 - 0.03)

<0.001
<0.001
0.95

Reference
1.10 (0.55 - 2.26)
1.06 (0.62 - 1.81)
0.90 (0.51 - 1.61)
1.09 (0.52 - 2.28)
0.74 (0.53 - 1.05)
0.97 (0.52 - 1.79)
0.81 (0.58 - 1.14)

0.78
0.85
0.73
0.82
0.09
0.91
0.23

1.38 (0.98 - 1.94)
1.09 (0.76 – 1.57)
1.2 (1.06 – 1.39)

0.06
0.63
0.005*
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Caregiver HHV-8 status(enrollment) (Ref: Negative)
Any other household member HHV-8 status (Ref: Negative)
Increasing number of HHV-8 positive household members
a
Significant at α level of 0.05

0.75 (0.53 - 1.04)

Table 4. Univariable Analysis to Investigate the Association of Breastfeeding Practices, Premastication, and Adult Feeding
Behavioral Habits with Child HHV-8 Seroconversion in Lusaka, Zambia, 2004-2009.
Hazard Ratio (95% CI)

P-value

Breastfeeding practices
Child breastfed in the past, currently weaned

1.24 (0.79 - 1.95)

0.34

Child is currently being breastfed

6.26 (4.02 - 9.75)

<0.0001*

3.15 (1.00 - 9.98)

0.05*

3.15 (0.44 - 22.71)

0.25

3.39 (1.75 - 6.60)

0.0003*

5.52 (2.00 - 15.20)

0.0009*

4.13 (2.37 - 7.19)

<0.0001*

4.45 (1.92 - 10.29)

0.0005*

4.44 (2.05 - 9.60)

0.0002*

Primary caregiver sharing of eating utensils w/ child

4.28 (2.07 - 8.85)

<0.0001*

Other household members sharing of utensils w/ child
Significant at α level of 0.05

3.53 (1.54 - 8.12)

0.003*

Premastication
Caregiver premasticates food prior to sharing with
children
Other household members perform the premastication
Adult feeding variables
Primary caregiver testing temp of food with tongue prior
to sharing w/ child
Other household members testing temp of food with
tongue
Primary caregiver blowing on food prior to sharing w/
child
Other individuals blowing on food prior to sharing w/
child
Eating of food with hands from a common bowl

a
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Characteristic

Table 5. Univariable Analysis to Investigate the Association of Child Behaviors of Sharing Sweets and Drinks with Child HHV-8
Seroconversion in Lusaka, Zambia, 2004-2009.
Characteristic
Child sharing variables
Primary caregiver sucking on sweets prior to sharing w/
child
Other household members sucking on sweets prior to
sharing w/ child
Other non-household members sucking on sweets prior to
sharing w/ child
Index child shares food, candy or other sweets with other
household children
Index child shares food, candy or other sweets with other
neighborhood children
Exchange of food, candy or other sweets from another
child's mouth to Index child
Primary caregiver sharing of packaged drinks w/ child
Other household members sharing of packaged drinks w/
child
Other non-household members sharing of packaged drinks
w/ child
Neighborhood children sharing of packaged drinks w/
child
Use of pacifier
a
Significant at α level of 0.05

Hazard Ratio (95% CI)

P-value

2.06 (0.90 - 4.74)

0.09

2.87 (1.38 - 5.97)

0.005*

3.54 (1.43 - 8.74)

0.006*

2.97 (1.57 - 5.61)

0.0008*

3.06 (1.12 - 8.37)

0.029*

2.54 (1.27 - 5.10)

0.008*

3.36 (1.54 - 7.33)

0.002*

4.87 (2.32 - 10.21)

<0.0001*

7.44 (2.68 - 20.69)

0.0001*

5.36 (1.95 - 14.75)

0.001*

17.62 (4.18 - 74.35)

<0.0001*
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Table 7. Univariable Analysis to Investigate the Association of Hygiene and Health Practices with Child HHV-8 Seroconversion in
Lusaka, Zambia, 2004-2009.
Characteristic

Hazard Ratio (95% CI)

P-value

Hygiene practices
<0.0001*

Number of daily full-body baths for index child:
Once per day

Reference

Twice per day

4.35 (2.88 - 6.57)

<0.0001*

Twice or more daily

0.83 (0.50 - 1.39)

0.48
<0.0001*

Number of daily face cleanings for index child:
Once per day

Reference

Twice per day

3.95 (2.47 - 6.31)

<0.0001*

Twice or more daily

0.54 (0.32 - 0.90)

0.02

Primary caregiver sucking mucus from child's nose

3.95 (2.47 - 6.31)

0.58

Primary caregiver used saliva to clean child's face

0.54 (0.32 - 0.90)

0.41

Use of Ashton Powder to relieve teething pain

1.72 (0.24 - 12.39)

0.06

Use of toothbrushing to clean teeth

2.30 (0.32 - 16.50)

0.37

Primary caregiver biting the child's nails to shorten them

3.91 (0.94 - 16.18)

0.45

Other household members biting the child's nails to shorten them

0.63 (0.23 - 1.71)

0.16

Lifebuoy soap for constipation

1.72 (0.42 - 6.98)

0.20

Health practices

Significant at α level of 0.05
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a

Table 8. Univariable Analysis to Investigate the Association of Childhood Interaction Practices with Child HHV-8 Seroconversion in
Lusaka, Zambia, 2004-2009.
Characteristic

Hazard Ratio (95% CI)

Childhood interaction variables
Number of playmates:

P-value

<0.0001*

None

2.50 (0.61 - 10.20)

2-3

1.41 (0.75 - 2.68)

0.29

>3

0.61 (0.33 - 1.12)

0.11

Don’t know

8.33 (1.05 - 65.93)

0.04
<0.0001*

Number of playmates under the age of 5
None

Reference

2-3

1.16 (0.64 - 2.11)

0.63

>3

0.52 (0.29 - 0.92)

0.02

Don’t know
Index child has spent the night at someone
else's house within the last 6 months
Visiting child has spent the night at Index
child's house within the last 6 months
a
Significant at α level of 0.05

7.14 (0.91 - 55.81)

0.06

4.25 (1.55 - 11.63)

0.005*

7.18 (1.74 - 29.58)

0.006*
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Table 9. Multivariable Analysis to Investigate Independently Associated Risk Factors Associated with HHV-8 Seroconversion in
Children in Lusaka, Zambia, 2004-2009.
Characteristic

Hazard Ratio (95% CI)

<0.0001

Age at Seroconversion:
<24M
>24M to ≤36M

P-value

Reference
0.16 (0.09 - 0.28)

<0.001

0.006 (0.002 - 0.016)

<0.001

Age at enrollment (Ref: <12M)

2.62 (1.64 - 4.21)

<0.001

Child is currently being breastfed

2.13 (1.31 - 3.44)

0.002

Use of pacifier

9.00 (1.65 - 49.19)

0.01

>36M

0.0006

Number of daily full-body baths for index child:
Once per day

Reference

Twice per day

2.18 (1.40 - 3.38)

0.0005

Twice or more daily

0.94 (0.54 - 1.62)

0.8102

38.69 (4.50 - 332.75)

0.0009

2.26 (1.19 - 4.30)

0.013

2.79 (1.01 - 7.76)

0.05

Primary caregiver used saliva to clean child's face
Child HIV status (Ref: Negative)
Other individuals blowing on food prior to sharing
w/child
a
Significant at α level of 0.05
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FIGURE LEGEND
Figure 1.
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N = 1600
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n =254
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HHV8- Children
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HHV8+ Children
n = 75
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n =119

HHV8- Children
n = 270
Seroconverters
HHV8+
n = 137 (50.7%)

Non-seroconverters
HHV8n = 133 (49.3%)

Figure 1. Flow Chart outlining the screening and recruitment of study cohort in Lusaka,
Zambia, 2004-2009.
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Figure 2. Results from Kaplan-Meier survival analysis estimating the probability of a child seroconverting to become positive for
HHV-8 in Lusaka, Zambia, 2004-2009. Results are represented by the total cohort (n=270) (panel A); males vs. females (panel B);
human immunodeficiency virus type 1 (HIV-1) infection status of the mother at enrollment (panel C); HIV-1 infection status of the
child at time of seroconversion (panel D).
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ABSTRACT
Human herpesvirus-8 (HHV-8) or Kaposi’s sarcoma-associated herpesvirus (KSHV) has
been linked to all forms of Kaposi’s sarcoma (KS). Most current serological assays to
detect HHV-8 antibodies have low concordance amongst themselves. To establish a
sensitive and specific testing strategy to screen for HHV-8 antibodies, three HHV-8
proteins, ORF65, ORF73 and K8.1A, were expressed using baculoviral vectors in insect
cells and incorporated into an monoclonal-enhanced immunofluorescence assay (mIFA)
termed Sf9 3-antigen mIFA. The results with this monoclonal-enhanced mIFA were
compared to those obtained with a standard mIFA utilizing a HHV-8 infected B-cell line
(BC3 mIFA). Test sera were obtained from patients with diagnosed KS, HIV-1 infected
patients at high risk for HHV-8 infection, and healthy controls from a local blood bank.
Combined use of both assays together had a sensitivity of 94% and a specificity of 96%.
The performance of these two assays when used together indicates that they may be
useful for reliable detection of HHV-8 IgG antibodies in a population.
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INTRODUCTION
Human herpesvirus 8 (HHV-8), also known as Kaposi’s sarcoma-associated
herpesvirus (KSHV), is the latest human herpesvirus identified. It has been associated
with all four clinical presentations of KS (classic, endemic, AIDS related and the
iatrogenic form) Kaposi’s sarcoma (KS) [6, 15]. HHV-8 has also been detected in
primary effusion B-cell lymphomas (PEL) and in multicentric Castleman’s disease
(MCD) [4, 30].
In the general population, HHV-8 seroprevalence shows marked geographical
variations. HHV-8 infection is endemic in Africa and the Mediterranean region and in
non-endemic areas is higher in homosexual men and immunosuppresed individuals [8, 9,
13, 24]. Routes of transmission are still not well understood but both horizontal and
vertical transmission are possible [2, 10, 21]. Horizontal transmission can occur by sexual
and non-sexual routes. HHV-8 seroconversion is observed during adulthood in most
developed countries, most likely due to sexual transmission, and occurs in childhood in
endemic areas, most likely due to non-sexual horizontal transmission. HHV-8 DNA has
been detected in saliva making it to be a potential source of transmission via close
interpersonal contact [1-3, 9, 18, 22, 31]. HHV-8 DNA cannot be detected in all infected
individuals therefore; serology is the method of choice in epidemiological studies to
screen for infected individuals.
Development of high performance serologic tests has been achieved to a limited
degree only due to an incomplete understanding of the known immunodominant proteins,
lack of well characterized uninfected and infected individuals that serve as controls and
reported wide variations in antibody titers among infected individuals. While various
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serological assays have been shown to have variable performance and concordance,
immunofluorescence assays have been considered as one of the most sensitive assays for
detecting antibodies against HHV-8 [11, 23, 27]. IFA was one of the first assays to be
used for the detection of HHV-8 antibodies [20]. Cell lines derived from PEL and
chronically infected with HHV-8, expressing mainly latent and a low level of lytic
antigens have been used for latent or lytic IFAs. The level of lytic antigens can be
increased by induction with tetradecanoyl phorbol acetate (TPA). Using sera of KS
patients, several proteins have been identified as highly reactive antigens. These include
open reading frames (ORF) 6, 8, 9, 25, 26, 39, 59, 65, 68, 73, K8.1A and K8.1B [5]. Of
these proteins, ORF 59, K8.1A, ORF65, and ORF73 have been used in the development
of various enzyme immunoassays (EIA) and reported to be good candidate antigens [5,
14, 16, 19, 28, 32]. There are now two commercially available EIAs using whole virus
lysate and synthetic peptides.
Here we report the use of a screening strategy for detecting HHV-8 antibodies in
plasma samples. IFA utilizing Sf9 cells expressing predominant proteins encoded by
HHV-8 (ORF65, ORF73, K8.1) was used in conjunction with IFA utilizing stimulated
BC3 cells to obtain a sensitive and specific testing strategy.
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MATERIALS AND METHODS
Cell culture: BC-3 cells (ATCC) were grown in RPMI 1640 supplemented with 20% fetal
calf serum, L-Glutamine, sodium pyruvate, HEPES and D-glucose. Sf9 insect cells were
maintained as suspension culture in SF 900 II medium (Invitrogen, CA) supplemented
with 20% fetal calf serum and 1% gentamicin.
Patient sera: A total of 219 samples were used in this study. Of these, 108 samples were
collected from patients visiting the Adult Oncology unit at the University of Miami
Miller School of Medicine. Two KS plasma samples were collected from the University
Teaching Hospital, Lusaka, Zambia as a part of an ongoing study to investigate HHV-8
transmission within families. Blood banks at Lincoln, Nebraska and Kansas City, Kansas
contributed 109 plasma samples. Ethics committee of the Institutional Review Board at
the University of Nebraska approved the study. All samples were coded and screened
without knowledge of identity of the patient or the diagnosis. Subsequently, patient serum
samples were divided into 3 groups. Group A (positive group) consisted of a total of 33
samples collected from histologically identified KS patients. This group also included
samples from one PEL and one MCD patient. Group B (high risk group) consisted of 77
samples collected from HIV-1 positive patients with other cancers (not KS and PEL).
Group C (negative group) consisted of 109 samples collected from healthy blood bank
donors with low risk life style behaviors.
Preparation of BC-3 slides: BC3 cells at a concentration of 7 X 105 per ml were treated
with tetradecanoyl phorbol acetate (TPA) at a final concentration of 20 ng/ml for 72 hrs.
The cells were fixed in 4% paraformaldehyde for 20 min at room temperature, washed
with PBS and permeabilized with 0.1% Triton X 100 for 15 minutes at room temperature.
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The cells were washed and resuspended in PBS. Approximately 10 cells were spotted
4

per well onto 12 well teflon coated slides (Electron Microscopy sciences, PA) and stored
at -80 ºC.
Preparation of Sf9 cell slides expressing HHV-8 antigens: Recombinant baculoviruses
expressing glutathione S-transferase (GST) tagged lytic proteins, ORF65 and K8.1A, and
latent protein, ORF73 (provided by Dr Bala Chandran, Rosalind Franklin University of
Medicine and Science, Chicago), were used to develop the Sf9-mIFAs. Baculovirusinfected Sf9 cells expressing GST alone were used as a negative control to detect
background and nonspecific fluorescence. All baculovirus stocks were titrated and
infections were initiated separately with the three baculovirus stocks each of which
expressing one recombinant HHV-8 protein at a MOI of 10. Infected cells were
monitored daily for viability and cell diameter using Vi-Cell counter (Beckman-Coulter,
CA). The expression of each protein was evaluated by Western blot analysis with antiGST antibody (Santa Cruz Biotechnology, CA) following SDS-PAGE (Figure 1). At 72
hours post-infection (hpi) cells were harvested, mixed in equal ratio (1:1:1) of viable cells
and subsequently fixed using the BC3 cell method. This was called as the ‘Sf9 3-antigen’
test. All fixed slides were stored at - 80 ºC.
A modification of the method was also used. At 72 hpi, Sf9 cells infected with
baculovirus expressing ORF73, ORF65 or K8.1 antigens were harvested, fixed and
spotted individually on separate slides. This method was used to screen patients for the
presence of latent or lytic antibodies and is refered to as ‘single-antigen Sf9’ assay
Monoclonal-enhanced immunofluorescence assay (mIFAs): All serum samples were
diluted 1:40 and centrifuged at high speed for one minute immediately before being used.
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All slides were warmed to room temperature, individual serum samples were applied to
each well and the slides were incubated at 37 ºC for 30 minutes in a humidified chamber.
The slides were washed (6 times) with PBS and then incubated with mouse anti-human
IgG monoclonal antibody at 37 ºC for 30 minutes. The slides were washed with PBS
again and then incubated with goat anti-mouse Cy2 conjugated antibody (Jackson
Laboratories, City) at 37 ºC for 30 minutes. After washing, the cells were stained with
0.004% Evan’s blue for 5 minutes, washed and mounted. The procedure of mIFA was the
same for BC3 and Sf9 slides.
Criteria for being HHV-8 seropositive: All slides were read by two independent readers
without knowledge of patient identity, clinical diagnosis, HIV-1 status or the other
reader’s results. To reduce subjectivity in observing specific fluorescence, slides were
read independently by two experienced laboratory workers. A sample was considered
positive if specific fluorescence was observed by both readers. In case of discordant
results the assay was repeated. On repetition if discordant results were again obtained
then these patients were considered seronegative. All samples determined to be positive
by BC-3 mIFA and the Sf9 3-antigen assay were considered positive. If a patient was
positive on just one assay or negative by both assays, it was considered as HHV-8
negative. This testing scheme is summarized in Figure 2.
Statistical analysis: All data was entered and analyzed using SPSS (v15). Kappa statistic
was computed to determine the concordance between the standard BC3 mIFA and the
Sf9 mIFA. Sensitivity of detection of HHV-8 antibodies was calculated as: True positives
/ (True positives + False Negatives). All serum samples collected from reliably diagnosed
cases of KS, PEL and MCD and found serologically positive by both assays were
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considered as true positives. Results were considered false negative if serum samples
collected from these patients were found to be negative by our criteria.
Specificity was calculated as True Negatives/(True Negatives + False Positives). All
serum samples collected from healthy blood donors and found serologically negative by
either assay were considered as true negatives. Results were considered false positive if
samples collected from these patients were found to be positive.
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RESULTS
HHV-8 seroprevalence
All serum samples were assigned a unique identification number and were
screened blinded using both mIFAs. Representative mIFA images of a positive and
negative patient are shown in Figure 3. After serological screening was completed, the
specimens were divided into 3 groups based on their clinical diagnosis as described in
Materials and Methods section (Table 1). Using the strategy described in Figure 2, in
Group A (KS/PEL/MCD) the overall seroprevalence was 93.9%. Two samples were
considered seronegative, including one sample which tested positive by BC3 mIFA but
negative by Sf9 3-antigen mIFA and a second sample that was not positive by either of
the two assays. In Group B, (high risk group) the seroprevalence was 58.4 % with 45 out
of 77 samples being positive by both assays. The remaining 32 samples were considered
seronegative. Fifteen out of these 32 seronegative samples (19.5%) were negative by both
assays. There were 9 (11.7%) and 8 (10.4%) samples that were positive by BC3 and Sf9
3-antigen assay alone, respectively. In Group C (blood bank donors) both assays detected
HHV-8 antibodies in only 4 (3.6%) of the patients. The remaining 105 samples were
considered seronegative. Of these 105 seronegative samples, 2 (1.8%) and 7 (6.4%) were
positive by BC3 and Sf9 3-antigen assay alone, respectively.
Latent and lytic antibody profiles
All samples that were positive on Sf9 3-antigen assay were screened using the
single-antigen Sf9 method to ascertain the latent and lytic antibody profiles present in
different groups. Also, we compared the antibody profiles of those samples that were
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positive with both BC3 mIFA and Sf9 3-antigen assays to samples that were BC3 mIFA
negative and Sf9 3-antigen positive (Table 2).
BC3 and 3 antigen positive samples - When mIFAs were performed using ORF65, K8.1
and ORF73 antigens separately, 74% (23/31) of Sf9 3-antigen and BC3 mIFA positive
samples in Group A reacted to both latent (ORF73) and lytic (ORF65 or K8.1) antigens.
Two samples had detectable antibodies against latent antigen only and 6 samples reacted
to at least one lytic antigen. In Group B, 64% (29/45) of seropositive samples reacted to
both latent and lytic antigens. There were 8 samples each that reacted only to either latent
or lytic antigen. In Group C, there was only 1 out of 4 seropositive samples that was
positive for both latent and lytic antigens. There were 3 samples that were positive for
lytic antigens only.
BC3 negative and 3 antigen positive samples - We also wanted to compare the above
antibody profiles of patients who were negative by BC3 mIFA. We did not find any such
sample in group A but there were 6 of those samples in Group B. All these 6 samples
were negative by BC3 mIFA and had detectable titers to both latent and lytic antigens as
observed by using the 3-antigen assay. In the same Group there was one sample each that
was positive for latent or lytic antigens only. In Group C individuals, we observed that
there was only one sample that was positive for both latent and lytic antigens, but 6
samples that reacted positively to lytic antigens.
Concordance, assay sensitivity and specificity
Kappa value (κ-value) denoting the concordance of BC3 mIFA and Sf-9 3-antigen
assay was calculated. The overall κ-value of all the 219 samples was 0.75. The sensitivity
of the screening strategy was then evaluated by using group A (positive group) samples
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and calculated as described in the Materials and Methods section. Sensitivity of detecting
positive samples by this combined strategy was 93.9%. The specificity was calculated by
using group D (blood bank donors) samples. This yielded a specificity of 96.3%.
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DISCUSSION
A large proportion of infected but asymptomatic individuals do not have
detectable viral DNA in peripheral blood therefore, thus serology is a more reliable
method to identify infection. But a major hurdle in obtaining clear seroprevalence data in
a population, understanding the route of transmission and routine monitoring of ‘at risk’
individuals, is the lack of a reliable assay that can detect antibodies in human sera.
Most laboratories use ‘in house’ assays with varying levels of sensitivity and
specificity and concordance for screening of HHV-8 antibodies [23, 26, 27]. Currently no
assay is clearly superior in terms of sensitivity and specificity. Our goal was to develop a
sensitive and specific Sf9 3-antigen IFA that is cost effective and can be used as a
confirmatory test to validate IFA results using HHV-8 infected cells. In this report both
BC3 assay and Sf9 3-antigen assay were used in parallel to investigate the concordance
of the two assays. Given the findings in this report, the Sf9 3-antigen assay can be used in
tandem as a confirmatory assay with BC3 assay, for screening for HHV-8 antibodies. To
evaluate the sensitivity and specificity of this testing strategy, we used samples from well
characterized patients. Both BC3 and Sf9 3-antigen mIFAs are designed to detect HHV-8
specific IgG antibodies against latent and lytic antigens. ORF73 is the major latent
protein and encodes for latency associated nuclear antigen (LANA). ORF65 is a lytic
phase protein and encodes for minor capsid antigen. ORF65 has been reported to be one
of the immunodominant antigens that can be used for a sensitive serological assay [17].
Sf9 3-antigen assay is flexible because it can be expanded to incorporate more antigens if
needed. Overexpression of the immunodominant proteins also helps to easily identify
patients having very low titer of HHV-8 antibodies. In Sf9 cells, each antigen can be

138
expressed individually to monitor antibody responses to latent and lytic antigens
separately. More importantly, the use of a GST-expressing Sf9 cells served as bonafide
negative controls that were used to check for non-specific binding and fluorescence. Lack
of matched negative control cells is one of the major drawbacks of assays based on the
use of BC3 cells. Background or non-specific fluorescence which is commonly found in
immunofluorescence assays cannot be ruled out when using BC3 or other HHV-8
harboring cell lines. Populations which have been shown to produce this nonspecific
reactivity include serum samples from individuals with a high number of sexual partners,
patients with parasitic infections and among people exposed to a high number of
pathogens. Residue, sediments or high lipid content can also cause high background and
was controlled in our assay by centrifugation of each sample immediately before being
used [7].
Our criterion to consider a patient as positive in our study was based on two
immunofluorescence assays. A patient was considered positive if the plasma sample gave
specific fluorescence at a dilution of 1:40 by both IFAs. While this strategy increases the
specificity of detecting HHV-8 antibodies it may decrease the sensitivity of detection. By
using this testing strategy we could detect HHV-8 antibodies in 94% of clinically
diagnosed cases of KS, PEL and MCD. In the positive patients with KS there was one
patient that was negative by both BC3 and Sf9 IFAs. This patient has undergone
antiretroviral treatment after the development of KS, which could have suppressed the
viral load and led to complete seroreversion for HHV-8 antibodies by then. Seroreversion
has in fact been documented in patients after treatment and regression of symptoms [25].
CD4+ cell count data was not available to help gauge the level of immunosuppression
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which may also help explain the unexpected HHV-8 seronegativity. It is possible that the
sensitivity of both the assays was too low to detect the very low antibody titer in this
patient. One sample in the positive group was positive by BC3 mIFA but negative by Sf9
mIFA. This could be non-specific fluorescence shown by BC3 mIFA and cannot be
reliably confirmed because of lack of matched negative cell line. It is also likely that for
this patient none of the three antigens that were expressed in Sf9 cells were eliciting an
immune response and further underscores the importance of using multiple antigens for
screening. This suggests that there is a need for identification and incorporation of more
antigens for routine screening of patients.
We had chosen the blood bank donor group as our truly negative controls because
they are selected for minimal behavioral risk. Using this testing scheme, we found a
seroprevalence of 3.7% in this group. This is not surprising because a low seroprevalence
of about 3% has been reported in United States blood donors [23]. We observed a similar
seroprevalence in the blood bank donors which we had assumed to be negative. In our
case it reduced the specificity (96%) of this testing strategy. The lack of a “gold standard”
serological assay that can reliably identify patients that are truly infected versus those that
are uninfected makes it difficult to test the accuracy of the assays currently in use.
Group B patients were included as a test group. The seroprevalence in Group B
samples was within the expected range. HIV-1 infected patients from North America
have been reported to have HHV-8 seroprevalence in the range of 20-50% [12, 20, 29].
We observed a similar seroprevalence rate of 58.4% in this group. The antibody profile
showed that 82% of the seropositive samples had lytic antibodies which is indicative of
active replication and has been shown to be a risk factor for development of KS. No
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follow-up was available for these patients and we do not know if any of these developed
KS.
This assay could have some other drawbacks. It is more labor intensive than EIA
and reading of slides can be subjective. We tried to reduce the subjectivity effect by
employing two readers who read all the slides independently. EIA’s have frequently
employed KS patients to obtain cutoff values for optical density. This approach might
exclude asymptomatic individuals who are seropositive and frequently have very low
titer of HHV-8 specific antibodies. This method has proved to be adequately sensitive in
detecting HHV-8 specific antibodies from asymptomatic children and adults in Zambia;
an endemic region for HHV-8 infection (manuscript submitted). In our experience most
of the asymptomatic individuals in this cohort in Zambia have very low antibody titer and
EIA’s utilizing high cutoff values are not suitable for conducting such epidemiological
studies. We believe that our stringent criteria of detection may still be underestimating
the number of seropositive cases and reducing the level of sensitivity. But this scheme
increases the specificity of detection of HHV-8 antibodies by excluding false positives.
For this study we did not test these patient samples to other known ubiquitous
herpesviruses. Our observations from other adult patient samples from similar locations
have shown a very high seroprevalence.
Reliable serological assay could be a useful tool in the accurate monitoring and
diagnosis of HHV-8 infection. In the absence of a gold standard this strategy has proven
helpful in conducting seroepidemiological studies in an endemic area. A better
understanding of HHV-8 antibody response is required to perfect the current serological
testing strategy. In conclusion, we describe a new serological approach to screen patients
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for the presence of HHV-8 antibodies that is sensitive and specific and reduces the
chances of detecting false positives. Finally, further refinement of this approach to
incorporate more antigens is ongoing.
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TABLES AND FIGURES
Table 1: Seroprevalence of HHV-8 antibodies in positive control, high risk and blood
bank donors.

HHV-8 Positive
BC3+/3-antigen+
HHV-8 Negative
BC3+/3-antigenBC3-/3-antigen+
BC3-/3-antigen-

Positive group

High risk group

Negative group

n (%)

n (%)

n (%)

31 (94.0)

45 (58.4)

4 (3.7)

1 (3.0)
0
1 (3.0)

9 (11.7)
8 (10.4)
15 (19.5)

2 (1.8)
7 (6.4)
96 (88.1)

Note: Positive sign (+) refers to patients who tested positive and negative sign (-) refers
to patients who tested negative by that assay.

Table 2: Antibody profiles of all Sf9 3-antigen positive samples, against latent (ORF73) and lytic (ORF65 or K8.1) antigens.
Positive group
Latent

High risk group

Negative group

Lytic

+

+

BC3+
23

+

-

2

.

8

1

.

.

-

+

6

.

8

1

3

6

31

0

48

8

4

7

Total

BC3.

BC3+
29

BC36

BC3+
1

BC31

Note: Positive sign (+) refers to patients who tested positive and negative sign (-) refers to patients who tested negative
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FIGURE LEGENDS
Figure 1.

Figure 1. Western blot analyses of ORF65, ORF73 and K8.1A proteins expressed in Sf9
insect cells. Infected cells were harvested at 72 hours post-infection and lysed by
sonication. Specific proteins were detected by using anti-GST antibodies: Lanes 1-3,
ORF65 (48 kda), ORF73 (>150 kda) and K8.1A (52 kda), respectively. Arrows indicate
the expressed proteins.
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Figure 2.
Patient plasma
Screened by both
assays

BC3 assay

-

Sf9 3-antigen assay

+

+

Sf9 3-antigen assay

BC3 assay

-

Seropositive patient
+
+

-

-

Figure 2: Scheme followed to screen patients for HHV-8 antibodies and determining
their serostatus.
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Figure 3.

Figure 3. Representative staining patterns of mIFAs of ORF65, ORF73 and K8.1A
proteins expressed in Sf9 insect cells and of BC3 cells using a positive (KS) (left
column) and a negative (blood bank donor) (right column) patient sera.
by that assay.
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CHAPTER 6: CONCLUDING REMARKS
Human herpesvirus-8 is the etiologic agent for several malignant pathologies,
including body cavity-based B-cell lymphoma (BCBL), primary effusion lymphoma
(PEL), multicentric Castleman’s disease, and Kaposi’s sarcoma (KS). The onset of the
HIV epidemic in sub-Saharan Africa where HHV-8 is endemic has led to an increase in
KS incidence from 3.2% to 19%, making KS the most common tumor in children in subSaharan Africa [1-3]. Although several epidemiologic studies have examined
transmission risk factors in adults, there is a paucity of data about the transmission of
HHV-8 to susceptible children.
Several studies have implicated saliva as the mode of perinatal transmission, as
HHV-8 DNA is readily isolated from buccal swabs and whole saliva [4, 5]. In early
childhood, close contact with caregivers, household feeding practices, health care
practices, and child-rearing behaviors all are possible sources of saliva exposure. In
Zambia, additional traditional and cultural practices also can increase saliva sharing [6].
Our overall hypothesis is that household behaviors that expose the child to saliva increase
the risk of transmission of HHV-8 to the child. To test our hypothesis, we launched the
Zambia KS-HHV-8 Study, a large prospective cohort study in Lusaka, Zambia, to follow
young children and their households, investigating incidence and associated risk factors
in early childhood HHV-8 infection.
In the undertaking of any large epidemiologic investigation, careful planning of
study design is essential to attain reliable results. In chapter 2, the study design, the
methodology in cohort development, the recruitment, screening and enrollment are
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described in detail. Loss to follow-up is a great concern in large studies and was a
challenge in our earlier Zambian study of mother and infant pairs [7]. To minimize this,
we utilized community workers to assist in recruitment process, follow-up and participant
retention. In total, 1,600 households were screened and 368 households comprised of
464 children were enrolled.
Chapter 3 examines the seropositivity of HHV-8 in children at enrollment of the
cohort, and associated behavioral risks. This is a cross-sectional study of 75 children
found to be HHV-8 positive and their households. Key findings were the risk for HHV-8
infection included increasing number of HHV-8 positive household members [OR 2.5
(95% CI: 1.9, 3.3) P < 0.01] and having a primary caregiver who tested the temperature
of food with their tongue prior to feeding the child [OR 2.4 (95% CI: 1.93, 3.30) P
=0.01]. Breastfeeding was protective against infection with HHV-8 for children [OR 0.3
(95% CI: 0.16, 0.72) P <0.01].
In chapter 4 we looked longitudinally at HHV-8 negative children, examining
incidence of HHV-8 infection, and the household and behavioral risks associated. Most
significant independent risk factors for HHV-8 seroconversion included age at
seroconversion (P < 0.0001), age at enrollment [HR 2.62 (95% CI: 1.64, 4.21) P < 0.001],
child currently being breastfed [HR = 2.13 (95% CI:1.31, 3.44) P = 0.002], use of pacifier
[HR = 9.00 (95% CI:1.65, 49.19) P = 0.01], child HIV-1 status [HR = 2.26 (95% CI:1.19,
4.30) P = 0.013], and other individuals blowing on food prior to sharing with child [HR =
2.79 (95% CI:1.01, 7.76) P = 0.05].
This dissertation also included a study on developing an analytical assay to detect
anti-HHV-8 antibodies. There is no gold standard for diagnostic assays for HHV-8.
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Wide variations reported in population prevalence studies for HHV-8 are often attributed
to the different diagnostic assays used [8]. As a part of launching the study in Zambia we
have to adapt the current assays to the study setting. This study describes the
development of a monoclonal immunofluorescent assay protocol using an HHV-8
infected B cell line (BC3), and a recombinant protein expressed in Sf9 insect cells to
screen patient plasma for HHV-8 antibody detection. A sensitivity of 94% and a
specificity of 96% is reported.
Overall, this dissertation describes the development of an epidemiologic study to
examine HHV-8 transmission within households, and the association of transmission of
HHV-8 to a susceptible child with behaviors that expose a child to saliva. Taken
together, the studies in this report suggest that associations between feeding habits that
expose a child to saliva are associated with the risk of early childhood acquisition of
HHV-8. Although our work supports that the most significant risk of HHV-8
transmission to a susceptible child lies with the primary caregiver, we know that
transmission can also occur with other household members and even outside of the
household [9].
Although other studies have looked at HHV-8 transmission in families, the studies
reported here are unique and have several strengths. The importance of longitudinal
studies in HHV-8 epidemiologic studies cannot be understated. It is well documented
that antibody titers can vary significantly across time, making antibody levels drop below
detection limits of most antibody detection assays [7]. This affects the validity of point
prevalence studies in HHV-8. In our study, trends across time could be monitored to help
insure accuracy of diagnostics.
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Another strength of our study is the cohort design. We enrolled very young
children, as young as 2 months of age to ensure enrollment of HHV-8 negative children.
Children become HHV-8 positive at a very young age, and investigating the influence of
behaviors as they occur is important in avoiding recall bias. Another important
component of our study is that our cohort was comprised of complete households. In
resource-poor counties, households often move frequently, and family members may
leave and reenter households due to work situations. Moreover, Zambian families
continue to be affected by the high mortality rates secondary to AIDs. Households are
often comprised of extended family as caregivers, or children from extended families
which may move in and out of the household on a frequent basis. Maintaining our cohort
and following complete households for 48 months allowed us to collect valuable
information for epidemiologic analysis. The final strength of our study is the detailed
questionnaire, allowing us to assess not only how HHV-8 transmission may occur, but if
the source is from the primary caregiver, other household members, or from
neighborhood children.
A surprising but interesting finding in our studies is the seemingly contradictory
effect of breastfeeding. In chapter 3, we report that breastfeeding was protective;
however in chapter 4 in looking at the longitudinal cohort, breastfeeding became a risk
for transmission. We believe that this is an important question that should be explored
further. It warrants exploring breast milk further for viral presence, and also
investigating for maternal antibodies that may be neutralizing. Future behavioral studies
are warranted, such as use of saliva on the nipples prior to feeding the child, or presence
of a confounding factor such as initiation of solid foods while breastfeeding.
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In summary, we have demonstrated that HHV-8 presence in the household plays a
key role in transmission of the virus to a susceptible child. This likely occurs through
saliva sharing during behaviors such as testing the temperature or blowing on food before
sharing to children.
The significance of this project is that understanding the possible source and route
of transmission of HHV-8 virus should lead to developing strategies to facilitate
behavioral changes to decrease the incidence of infection in children and the development
of KS. This supports the need for increased public awareness and education regarding
risks of viral transmission with child-feeding behaviors that expose children to saliva.
These findings have potential implications in public health, in identifying populations at
highest risk for evaluation, and potentially for possible future vaccine studies.
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